

**ISPAD CLINICAL PRACTICE CONSENSUS GUIDELINES**

# ISPAD Clinical Practice Consensus Guidelines 2018: Type 2 diabetes mellitus in youth

Phillip Zeitler<sup>1</sup> | Silva Arslanian<sup>2</sup> | Junfen Fu<sup>3</sup> | Orit Pinhas-Hamiel<sup>4</sup> | Thomas Reinehr<sup>5</sup> |  
Nikhil Tandon<sup>6</sup> | Tatsuhiko Urakami<sup>7</sup> | Jencia Wong<sup>8</sup> | David M. Maahs<sup>9</sup>

<sup>1</sup>Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado

<sup>2</sup>Children's Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

<sup>3</sup>The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China

<sup>4</sup>Edmond and Lily Safra Children's Hospital, Tel-Hashomer, Sackler School of Medicine, Tel-Aviv, Israel

<sup>5</sup>Vestische Children's Hospital, University of Witten/Herdecke, Witten, Germany

<sup>6</sup>All India Institute of Medical Sciences, New Delhi, India

<sup>7</sup>Nihon University School of Medicine, Tokyo, Japan

<sup>8</sup>Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia

<sup>9</sup>Lucile Packard Children's Hospital, Stanford University, Stanford, California

**Correspondence**

Phillip Zeitler, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO.

Email: philip.zeitler@childrenscolorado.org

**KEYWORDS:** ISPAD, type 2 diabetes, youth

## 1 | WHAT'S NEW

The 2018 ISPAD Guidelines have been updated based on published data and evolving expert opinion since the 2014 chapter was published, including treatment target (HbA1c = 7%) and intensification of management recommendations.

## 2 | EXECUTIVE SUMMARY

### 2.1 | Screening for T2DM in at-risk youth

1. Undiagnosed type 2 diabetes mellitus (T2DM) is rare in the adolescent population, even among high-risk individuals (A)
2. Generalized population screening of obese youth is unlikely to be cost-effective in most populations (E).
  - a. Urinary glucose screening in Japanese and Taiwanese adolescents may be a unique situation with demonstrated cost-effectiveness (A)
3. Testing to identify clinical cases of diabetes should be considered in children and adolescents after the onset of puberty or after 10 years of age, whichever occurs earlier, who have risk factors for diabetes (obesity, intrauterine growth retardation with rapid infant weight gain, first-degree family history of T2DM, maternal

history of diabetes or gestational diabetes during child's gestation, high-risk ethnicity, polycystic ovary syndrome). (A)

4. Clinical testing for dysglycemia in obese at-risk youth should occur in the setting of clinical assessment of other obesity-related comorbidities (non-alcoholic fatty liver disease [NAFLD], dyslipidemia, elevated blood pressure [BP], polycystic ovary syndrome) that are more prevalent than dysglycemia (A)

### 2.2 | Diagnosis and determination of diabetes type

1. T2DM in youth should be diagnosed using American Diabetes Association (ADA) criteria (A)
  - a. Diagnosis can be made based on fasting glucose, or 2-hour glucose concentration during an oral glucose tolerance test (OGTT) or hemoglobin A1c (HbA1c) (B)
  - b. In the absence of symptoms, testing should be confirmed with a repeat test on a different day
  - c. Clinicians should be aware of the weaknesses of each diagnostic test
2. Diabetes autoantibody testing should be considered in all pediatric patients with the clinical diagnosis of diabetes because of the high frequency of islet cell autoimmunity in otherwise "typical" T2DM (B)

- a. Pre-pubertal children are unlikely to have T2DM even if obese (A)
- b. Antibodies will indicate the diagnosis of T1DM and an earlier need for insulin (A)
- c. Antibodies will indicate the need to consider the presence of other associated autoimmune disorders (A)
3. Diabetes autoantibody testing should be considered in overweight/obese pubertal children with a clinical picture of T1DM (A)
4. The presence of clinically relevant comorbidities should be assessed at the time of diagnosis (A), including hypertension, dyslipidemia, elevation of liver enzymes, and elevated urine albumin/creatinine ratio (ACR)
5. Patients should be screened for obstructive sleep apnea (OSA), depression/anxiety, eating disorders, and impairment of cognition at the time of diagnosis (E). The possibility of pregnancy should be considered

### 2.3 | Initial treatment

1. Lifestyle changes should be recommended at the time of diagnosis of T2DM (A)
2. Initial pharmacologic treatment of youth with T2DM should include metformin and insulin alone or in combination, depending on degree of hyperglycemia and metabolic disturbances, and presence or absence of ketosis/ketoacidosis. B
  - a. Metabolically stable patients (HbA1c < 8.5 and no symptoms) should be started on metformin. (A)
    - i. Begin with 500-1000 mg (or 850 mg when this is the lowest available dose) daily  $\times$  7 to 15 days. Titrate once a week over 3 to 4 weeks, depending on patient tolerance, to a maximal dose of 1000 mg BID or 850 mg TID (extended release metformin product may be used where available).
  - b. In patients with ketosis/ketonuria/ketoacidosis, treatment with subcutaneous or intravenous insulin should be initiated to rapidly correct the metabolic abnormality (A).
    - i. Once a day intermediate-acting or basal insulin (0.25-0.5 units/kg starting dose) is generally effective in attaining metabolic control
    - ii. Metformin can be started along with insulin, once acidosis is resolved (E).
    - iii. Transition onto metformin monotherapy can usually be achieved safely over 2 to 6 weeks (A)
3. The goal of treatment should be an HbA1c < 7.0% (<47.5 mmol/mol). (B)
4. Self-monitored blood glucose (SMBG) should be performed regularly. The frequency of SMBG should be individualized, based on the degree of glycemic control and available resources (E). The benefits of continuous glucose monitoring have not been explored in youth-onset T2DM.

## 3 | SUBSEQUENT TREATMENT

1. If the patient fails to reach target HbA1c of <7% (<47.5 mmol/mol) within 4 months on metformin monotherapy, addition of

basal insulin (or intermediate-acting insulin where basal insulin is not available) should be strongly considered. (A)

2. If target is not attained on the combination metformin and basal insulin (up to 1.5 U/kg), prandial insulin should be initiated and titrated to reach target HbA1c < 7% (B)
3. Other pharmacologic agents are generally not approved for use in this population and their role in the management of glycemia in youth-onset T2DM is presently not determined (E)
  - a. The use of sulfonylurea agents is not recommended due to increased risk for hypoglycemia and more rapid loss of  $\beta$ -cell function (A)

### 3.1 | Assessment and management of comorbidities and complications

1. Urine ACR should be obtained at the time of diagnosis and annually thereafter: (A)
  - a. An elevated ACR (>30 mg/g creatinine or 3.39 mg/mmol) should be confirmed on two of three samples.
  - b. If urine ACR is confirmed to be >30 mg/g or 3.39 mg/mmol and BP is elevated, or if urine ACR is >300 mg/g irrespective of BP, angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) should be started and titrated with the goal of BP in the normal range (A)
  - c. Consider non-diabetes related causes of renal disease especially in the presence of ACR > 300 mg/g (33.9 mg/mmol); consider referral to a renal specialist.
2. BP should be monitored at every visit according to standardized techniques specific for children (A)
  - a. Elevated BP should be confirmed on 2 additional separate days
    - i. Hypertension is defined as an average systolic or diastolic BP > 95th percentile for age, sex, and height, with high normal BP being 90th to <95th percentile.
  - b. Initial treatment should consist of weight loss, limitation of dietary salt, and increased physical activity. (E)
  - c. If BP remains above the 95th percentile after 6 months, an ACE inhibitor should be initiated and titrated to achieve BP less than the 90th percentile (A)
  - d. If the ACE inhibitor is not tolerated due to adverse effects, an ARB, calcium channel blocker, or diuretic can be used. (E)
  - e. Combination therapy may be required if hypertension does not normalize on single agent therapy. (E)
3. Testing for dyslipidemia should be repeated once glycemic control has been achieved or after 3 months of initiation of medication, and annually thereafter. Initial screening does not require a fasting sample (B)
  - a. Cholesterol
    - i. Goal levels are (B):
      1. LDL-C < 100 mg/dL (2.6 mmol/L)
      2. HDL-C > 35 mg/dL (0.91 mmol/L)
      3. triglycerides <150 mg/dL (1.7 mmol/L)
    - ii. If LDL-C is above goal, blood glucose control should be optimized and dietary counseling should be provided using the American Heart Association Step 2 diet
    - iii. A repeat lipid profile should be performed fasting in 6 months. (B)

- iv. If repeat fasting LDL-C > 130 mg/dL (>3.4 mmol/L): begin medication with an initial goal of <130 mg/dL (<3.4 mmol/L): and an ideal target of <100 mg/dL (2.6 mmol/L (B)
- v. Statin therapy has been shown to be safe and effective in adolescents (A)
  1. The risks of pregnancy should be re-emphasized
- b. Triglycerides
  - i. If triglycerides are >400 mg/dL fasting (>5.6 mmol/L) or >1000 mg/dL (>11.3 mmol/L) non-fasting: begin medication with a goal of <400 mg/dL (>5.6 mmol/L) fasting (to reduce risk for pancreatitis) (C)
  - ii. Fibrates are the preferred medication category for hypertriglyceridemia and have been shown to be safe and effective in adolescents (A)
4. Retinal examination should be performed at diagnosis and annually thereafter (A)
5. Evaluation for NAFLD and non-alcoholic Steatohepatitis (NASH) by measuring ALT and AST should be done at diagnosis and annually thereafter (A)
  - a. Interpretation of ALT should be based upon sex-specific upper limits of normal in children (22 U/L for girls and 26 U/L for boys) and not individual laboratory upper limits of normal. (A).
  - b. NAFLD/NASH or other causes of chronic hepatitis should be considered for persistently (>3 months) elevated ALT >3 times the upper limit of normal (ULN) (C)
  - c. Patients should be referred to gastroenterology if liver enzymes remain elevated >3 times ULN despite weight loss and attainment of glycemic control. (E)
  6. Patients should be asked about menstrual irregularities, symptoms of hyperandrogenism, depression, anxiety, eating disorders, and sleep disturbance at diagnosis and regularly thereafter. (E). Patients with menstrual irregularities should be tested for hyperandrogenism
  7. Patients should be asked about smoking and alcohol use at diagnosis and regularly thereafter and these behaviors should be discouraged. (A).

## 4 | INTRODUCTION

T2DM in children and adolescents (youth-onset T2DM) has become an increasingly important public health concern throughout the world,<sup>1–10</sup> with unique characteristics and demographics. The incidence of T2DM in adolescents continues to increase in many countries.<sup>11</sup> Similarly, the prevalence of prediabetes, defined in adults as a state of high-risk for progression to diabetes, is increasing quickly in some developing countries with the increase of overweight and obesity.<sup>12</sup> Because of the relatively recent emergence of the problem in children and adolescents, there has been a limited evidence base leading to unique challenges in the diagnosis, management, and monitoring of these individuals. This limited evidence base is further complicated by differences in the characteristics and presentation of the disorder and approaches to treatment in developed and developing countries. In 2014, ISPAD developed guidelines for the diagnosis and management of children and adolescents with T2DM.<sup>13</sup> Since the

publication of the last guidelines, additional studies, including follow-up of individuals in the multi-center randomized controlled TODAY trial and continuation of the population-based SEARCH for diabetes in youth study, have provided further information that contributes substantially to understanding of T2DM. This chapter will discuss the diagnosis and presentation of T2DM, classification of diabetes type, initial and subsequent treatment, monitoring, and assessment and management of associated comorbidities and complications.

## 5 | DEFINITION, CLASSIFICATION, AND CHARACTERISTICS OF YOUTH-ONSET T2DM

T2DM occurs when insulin secretion is inadequate to meet the increased demand posed by insulin resistance, leading to relative insulin deficiency<sup>14</sup> and is generally associated with other metabolic abnormalities characteristic of insulin resistance (dyslipidemia, hypertension, polycystic ovary syndrome, fatty liver). Unlike T1DM, there is no identified autoimmune process leading to inadequate insulin secretion in T2DM, which appears to result from genetic, environmental, and metabolic causes that may differ between individuals and populations. Insulin secretion depends on disease status and duration and can vary from a delayed but markedly elevated peak in response to a glucose challenge initially, to absolutely diminished secretion over time.<sup>14</sup> Adults with symptoms of diabetes have 50% reduction in insulin secretion at the time of diagnosis and may become insulin dependent within a few years.<sup>15</sup> In adolescents at the time of diagnosis of T2DM, insulin secretion relative to their insulin sensitivity is impaired by ~85%.<sup>16</sup> Moreover, recent data from the TODAY (Treatment Options for T2DM in Adolescents and Youth) study suggest that deterioration in insulin secretion is even more rapid in adolescents than what has been reported in adults.<sup>2,17–20</sup> Furthermore, data from the TODAY<sup>21</sup> and SEARCH studies,<sup>22</sup> from studies of First Nations adolescents in Canada<sup>23</sup> and from diabetes registries in Australia<sup>24</sup> indicate that diabetes- and obesity-related comorbidities are prevalent at diagnosis in youth-onset T2D, increase rapidly over time, and are associated with worse morbidity and mortality than T1D diagnosed in the same age group.

The diagnosis of T2DM requires two steps: confirmation of the presence of diabetes followed by determination of diabetes type. The criteria and classification of diabetes are presented in greater detail in the ISPAD Clinical Practice Consensus Guidelines: Definition, Epidemiology, Diagnosis, and Classification of Diabetes (needs reference to that chapter) The diagnostic criteria for diabetes in youth are based on measurement of glycemia and the presence of symptoms.<sup>25</sup> There are four accepted ways to diagnose diabetes and each, in the absence of unequivocal symptoms of hyperglycemia, must be confirmed, on a subsequent day, by any one of the four methods given below.

According to the ADA,<sup>25</sup> diabetes is diagnosed when: (note: none of these criteria have been specifically validated in children and adolescents and are all extrapolated from adult definitions)

- Fasting plasma glucose (FPG)  $\geq 7.0$  mmol/L (126 mg/dL)
- Post OGTT 2-hour plasma glucose  $\geq 11.1$  mmol/L (200 mg/dL)
  - 1.75 g/kg (max 75 g) anhydrous glucose dissolved in water<sup>26</sup>

- Symptoms of diabetes and a random plasma glucose  $\geq 200$  mg/dL (11.1 mmol/L).
  - Symptoms of diabetes include polyuria, polydipsia, nocturia, and unexplained weight loss.
  - HbA1c  $\geq 6.5\%$  (48 mmol/mol)
  - Must utilize a laboratory based, DCCT aligned, National Glycohemoglobin Standardization Program (NGSP) certified methodology
  - Point-of-care measurement of HbA1c is not acceptable for diagnosis
- In the absence of symptoms, hyperglycemia detected incidentally or under conditions of acute physiologic stress may be transitory and should not be regarded as diagnostic of diabetes.
- The OGTT has poor reproducibility in adolescents, with a concordance rate between tests a few weeks apart of less than 30%.<sup>27</sup>
- Although the HbA1c criterion has been accepted by the ADA for the diagnosis of diabetes in adults, this criterion remains controversial, as it identifies a population that does not overlap entirely with that identified by fasting or post-glucose challenge criteria in adults or in youth.<sup>28-30</sup> However, HbA1c  $\geq 6.5\%$  (48 mmol/mol) predicts the risk for retinopathy in adults,<sup>25</sup> as well as the glucose criteria.
- Caution should be used in interpreting HbA1c, as the relationship between HbA1c and average glucose concentration can vary between different ethnic/racial populations<sup>31</sup> but appears to be consistent within an individual<sup>32</sup>

After the diagnosis of diabetes is established, diabetes autoantibody testing should be considered where available in all pediatric patients with the clinical diagnosis of T2DM because of the high frequency of islet cell autoimmunity in patients with “clinically” diagnosed T2DM. Studies have shown that autoantibodies are present in 10% to 20% of patients clinically diagnosed with T2DM, depending on the race and ethnicity of the population<sup>15,33-35,36,37</sup> The presence of antibodies predicts rapid development of insulin requirement,<sup>34</sup> as well as risk for development of other autoimmune disorders. Diabetes autoantibody testing should also be considered in overweight/obese pubertal children with a clinical picture of T1DM (weight loss, ketosis/ketoacidosis), some of whom may have T2DM and be able to be weaned off of insulin for extended periods of time with good control.<sup>38,39</sup>

## 5.1 | Characteristics of individuals with youth-onset T2DM

- Youth onset T2DM occurs most often during the second decade of life, with a median age of diagnosis of 13.5 years. This coincides with the peak of physiologic pubertal insulin resistance and, accordingly, the median age of onset is 1 year later in boys than girls.<sup>26,40</sup>
- Youth-onset T2DM rarely occurs prior to puberty.<sup>26,40</sup>
- Youth with T2DM come from families with a high prevalence of T2DM in first- and second-degree relatives.<sup>26,41</sup>
- Youth onset T2DM occurs in all races, but with a much greater prevalence in populations at overall high risk for type 2 diabetes,

- for example, American Indians, Canadian First Nations, Africans and African-Americans, Latinos, East and South Asians, Indigenous Australians and Pacific Islanders. The SEARCH for Diabetes in Youth study found the proportion of T2DM among 10 to 19-year-olds to vary greatly by ethnicity in the United States: 6% for non-Hispanic whites, 22% for Hispanics, 33% for African-Americans, 40% for Asians/Pacific Islanders, and 76% for Native Americans.<sup>4,40</sup> In Europe, there is a greater prevalence in immigrant populations from Asia, North Africa, and the Middle East.<sup>4</sup>
- In Hong Kong, 90% of youth-onset diabetes is T2DM,<sup>42</sup> 66% among Australian indigenous youth,<sup>43</sup> 60% in Japan, 50% in Taiwan,<sup>7</sup> but only 8% in China.<sup>11</sup>
- In the United States and Europe, nearly all youth with T2DM have body mass index (BMI) above 85th percentile for age and sex,<sup>26</sup> with the median BMI > 99th percentile. In Europe, nearly half of the adolescents with T2DM are extremely obese (BMI > 99.5th percentile).<sup>44,45</sup> However, in Japan, 15% of children with T2DM are not obese,<sup>10,46</sup> in South Asian urban children, half of those with T2DM had normal weight (<120% ideal for height),<sup>8</sup> and half of Taiwanese children with T2DM are not obese.<sup>7</sup>
- Youth onset T2DM has a sex ratio (male: female) that varies from 1:4 to 1:6 in native North Americans to 1:1 in Asians and Libyan Arabs. In some reports from China, the prevalence of T2DM in males is higher than in females.<sup>11</sup>
- In the United States and Europe, youth-onset T2DM is predominantly found in populations characterized by low socioeconomic and educational status,<sup>26</sup> while in emerging countries like China and India, more affluent children are more likely to develop T2DM than poorer children.<sup>8,11</sup>
- The presentation of youth-onset T2DM can vary from asymptomatic hyperglycemia detected through screening or during routine physical examination to ketoacidosis in up to 25% of patients<sup>47,48</sup> or hyperglycemic hyperosmolar state.<sup>49</sup> These latter two presentations can entail significant risk for morbidity and mortality if not recognized and appropriately treated.
- Youth-onset diabetes that has occurred in three consecutive generations, appears to be mild, but not responsive to Metformin should raise suspicion of the possibility of a form of monogenic diabetes in the young (MODY). (reference)

## 5.2 | Autoimmune “T2DM”

Some authors have reported the phenomenon of autoimmune T2DM. This has sometimes been referred to as T1.5DM, T3DM, or double-diabetes. However, these individuals are best understood as having autoimmune T1D presenting in overweight or obese individuals with underlying insulin resistance and associated metabolic abnormalities.

- Youth and adults in United States and Europe who are clinically diagnosed with T2DM are found to have T1D associated autoantibodies in 15% to 40% of cases, including many who are not receiving insulin 1 year after diagnosis.<sup>35-37</sup>
- Antibody-positive youth with the T2DM phenotype are significantly less overweight, have lower BP, lower triglycerides, higher

HDL-C, are less likely to be female and more likely to be non-minority than otherwise similar antibody negative patients.<sup>37</sup>

- $\beta$ -cell function is significantly lower in antibody-positive youth with T2DM phenotype, resulting in more rapid development of insulin dependence.<sup>37,50,51</sup>

### 5.3 | Uncertainties of classification

The clinician is obliged to weigh the evidence in each individual patient to distinguish between T1DM and T2DM. The reasons for this conundrum are:

- With increasing obesity in childhood, as many as 30% of newly diagnosed T1DM or patients with monogenic diabetes (MODY) may be obese, depending on the rate of obesity in the background population.
- A significant number of pediatric patients ultimately diagnosed with T2DM demonstrate ketonuria or ketoacidosis at diagnosis.<sup>48,52</sup>
- T2DM is common in the general adult population, with a positive family history for diabetes in 15% or greater in minority populations, reducing the specificity of a positive family history.
- Measurement of insulin or C-peptide is not recommended as part of routine evaluation. There is considerable overlap in insulin or C-peptide measurements between T1DM and T2DM at onset of diabetes and over the first year.<sup>40</sup> This overlap may be due to subjects being in the pre-symptomatic or recovery phase of autoimmune-mediated T1DM (the "honeymoon") and the effects of elevated glucose (glucotoxicity) and free fatty acids (lipotoxicity) to impair insulin secretion at the time of testing in both T1DM and T2DM. In addition, the insulin resistance of obesity may raise residual C-peptide levels in obese adolescents with T1D. Therefore, measurements are relatively valueless in the acute phase. However, persistence of C-peptide above the normal level for age is unusual in T1DM after 12 to 14 months.<sup>53</sup>
- Insulin resistance is present in both T2DM and T1DM, though the pathophysiology is different and resistance in T2DM is generally more severe.<sup>54,55</sup>
- Measurement of diabetes autoantibodies is the most rigorous approach to identification of T1DM. However, this measurement may be limited by lack of ready availability of standardized autoantibody assays, cost, involvement of antibodies not yet identified, and varying rates of antibody positivity in T1DM in different ethnic groups.
- While monogenic diabetes is rare in youth-onset diabetes overall, studies suggest that approximately 5% of individuals in some populations diagnosed with T2DM will have identifiable mutations associated with monogenic diabetes.<sup>56,57</sup> Monogenic diabetes can be confused with either T1DM or T2DM and requires a high-index of suspicion and recognition of autosomal dominant transmission in the family. The identification of monogenic diabetes has important clinical implications (50% likelihood of offspring being affected, better prognosis, fewer employment restrictions, possible avoidance of needing insulin) so that genetic testing should be considered where appropriate and available.

### 5.4 | Pre-diabetes: Diagnostic criteria (impaired glucose tolerance and impaired fasting glucose)

There are individuals whose glucose levels do not meet the criteria for diabetes, but are too high to be considered normal. Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) are intermediate stages in the natural history of disordered carbohydrate metabolism between normal glucose homeostasis and diabetes. The ADA has designated these physiologic state "pre-diabetes" to recognize the high risk for progression to diabetes in adults.<sup>25</sup>

- Prediabetes is diagnosed according to ADA definitions:
  - IFG: FPG  $\geq 5.6$  to 6.9 mmol/L ( $\geq 100$ -125 mg/dL)
  - IGT: Post-challenge plasma glucose is  $\geq 7.8$  to 11.1 mmol/L ( $\geq 140$ -199 mg/dL)
  - Hemoglobin A1c 5.7% to 6.4% (40-46 mmol/mol)
    - Laboratory-based, DCCT aligned, NGSP certified methodology
  - IFG and IGT are not interchangeable and represent different abnormalities of glucose regulation.<sup>58,59</sup>
- Individuals who meet the criteria for IGT or IFG may be euglycemic in their daily lives, as shown by normal or near-normal HbA1c and those with IGT may manifest hyperglycemia only when challenged with an OGTT. Conversely, some individuals may have elevated HbA1c but have normal OGTT, likely reflecting daily carbohydrate intake exceeding that associated with a standard glucose load.

The relevance of the concept and cut-offs for prediabetes, by definition a state of high risk for progression to diabetes in adults, is unclear in adolescents. However, data in youth demonstrate that  $\beta$ -cell function relative to insulin sensitivity is impaired even below the typically accepted cut points for fasting and the 2-hour glucose concentrations diagnostic of IFG and IGT.<sup>60,61</sup>

- In obese adolescents, pre-diabetes is often transient, with as many as 60% of individuals reverting to normal glucose tolerance within 2 years as the insulin resistance of puberty wanes.<sup>62</sup> Persistent weight gain is a predictor of persistent pre-diabetes and progression to diabetes.<sup>63</sup> Less than 2% of European adolescents with IFG or IGT develop T2DM in the next 5 years,<sup>64,65</sup> though this rate is higher among Latino and African-American youth.<sup>66</sup>
- Among minority adolescents in the United States, those with a laboratory measured HbA1c  $> 6\%$  (42 mmol/mol) have more than double the rate of progression to diabetes than those with an HbA1c 5.7% to 6% (39-42 mmol/mol).<sup>66</sup>
- Only lifestyle change, with decreased caloric intake and increased physical activity has been shown to be effective for adolescents with pre-diabetes.<sup>67</sup> There is currently no evidence base for the use of medications, such as metformin, for the treatment of prediabetes in adolescents and the low progression rate to diabetes in

this population indicates that many adolescents would be unnecessarily treated.

## 6 | TREATMENT OF YOUTH ONSET T2DM

### 6.1 | Management differences between T1DM and T2DM

The emergence of T2DM in children and adolescents has required that specialists familiar with the management of T1DM in children and adolescents recognize the vast differences between the treatment challenges of these two disorders.

- Differences in socioeconomic status: Whereas T1DM is distributed throughout the population proportionate to socioeconomic distribution, T2DM in developed countries disproportionately affects those with fewer resources, for example, lower income levels, less educated parents, and less well insured.<sup>26,40</sup> Conversely, in Asia and in other emerging economies, T2DM disproportionately affects the affluent.
- Older age: T1DM occurs throughout childhood, when parental influence is predominant, whereas T2DM occurs typically in adolescence, when peer influence predominates.
- More family experience: Only 5% of families with a child with T1DM have family experience with the disease, while more than 75% of families of the child with T2DM have such experience. Poor weight and glycemia control in these family members is common, with resultant complications and risk for a sense of fatalism.
- Gestational factors: More children with T2DM have either low or high birth weights and were exposed to gestational diabetes compared with those with T1DM.<sup>68,69</sup>
- Associated comorbidities and complications: Unlike T1DM, where diabetes related complications develop after many years of diabetes, many patients with T2DM will have comorbidities, such as fatty liver, sleep apnea, dyslipidemia, and hypertension<sup>22,26,70</sup> at the time of diagnosis and appear to develop microvascular and macrovascular complications at an accelerated rate. Therefore, screening for these abnormalities is recommended at the time of diagnosis and treatment may be required at the time of initiation of therapy for dysglycemia. Reduction in the rate of complications will require especially diligent attention to management of glycemia and aggressive treatment of comorbidities.<sup>15,18,24,71,72</sup> The complication rate of T2DM in European adolescents is lower than in the United States and Australia.<sup>45</sup>
- Lifestyle education: While education on diet and physical activity is important in all youth with diabetes, the need for intensive lifestyle intervention is a dominant feature of therapy in youth with T2DM<sup>73,74</sup> However, treatment adherence is a great challenge in lifestyle intervention of obese adolescents.<sup>74,75</sup>
- Because of the lower risk for hypoglycemia in T2DM, a lower HbA1c target is achievable in most adolescents with T2DM.

### 6.2 | Management goals

- Education for diabetes self-management
- Normalization of glycemia while minimizing hypoglycemia
- Weight loss
- Reduction in carbohydrate and calorie intake
- Increase in physical activity and exercise capacity
- Control of comorbidities and complications, including hypertension, dyslipidemia, nephropathy, sleep disorders, and hepatic steatosis

### 6.3 | Education

See also the ISPAD Clinical Practice Guidelines for diabetes education.<sup>76</sup> Initial and on-going education for T2DM should focus on behavioral changes (diet and activity), as well as education on administration of oral hypoglycemic agents and insulin as needed. The materials used to provide diabetes education in the TODAY trial were specifically designed to be age and culturally appropriate for English- and Spanish-speaking North American populations and are available for public use in both English and Spanish on the TODAY public website ([portal.bsc.gwu.edu/web/today](http://portal.bsc.gwu.edu/web/today)). They have also been modified and made available by the ADA as a program called *Be Healthy TODAY; Be Healthy for Life* (<http://www.diabetes.org/living-with-diabetes/parents-and-kids/children-and-type-2/>)

- Education should be given by team members with expertise and knowledge of the unique dietary, exercise, and psychological needs of youth with T2DM. The education and treatment team for T2DM ideally should include a nutritionist, psychologist and/or social worker, and exercise physiologist.<sup>76</sup>
- Education in T2DM places greater emphasis on healthy lifestyle habits including behavioral, dietary and physical activity changes than is generally required for T1DM.
- Education should be provided in a culturally sensitive and age-appropriate manner
- Because nearly all youth with T2DM are adolescents, the ISPAD Guidelines for Adolescent Care are appropriate to the education of youth and families with T2DM.<sup>77</sup>
- The entire family will need education to understand the principles of treatment of T2DM and to understand the critical importance of the lifestyle changes required of the entire family to successfully manage a youth with T2DM.
- Care providers should acknowledge that the initial uncertainty in the diagnosis of diabetes type in some patients can be confusing and anxiety-provoking for the youth and family. The anxiety can be minimized by emphasizing the importance of normalizing blood glucose metabolism using whatever therapy is appropriate to the metabolic circumstances of the specific individual, regardless of the eventual "type" of diabetes.
- Contraceptive counseling should be included, as well as a discussion of typical failure rates and the importance of using the contraceptive method consistently and correctly to avoid unplanned pregnancy in diabetes.

## 6.4 | Behavioral change

Lifestyle change is the corner-stone of treatment of T2DM and clinicians should initiate a lifestyle modification program, including nutrition and physical activity, for children and adolescents at the time of diagnosis of T2DM.<sup>78</sup> The interventions include promoting a healthy lifestyle through behavior change, including nutrition, exercise training, weight management, and smoking cessation.

- The family and child should understand the medical implications of obesity and T2DM.
- Clinicians must understand the health beliefs and behaviors of the family/community to design an effective behavioral plan.
- Changes should be made in small achievable increments and with the understanding that these changes need to be permanent.
- The patient and family should be trained to monitor the quantity and quality of food, eating behavior, and physical activity on a regular basis.
- As in any behavioral change, a dynamic and sustainable reward system is essential for success.

## 6.5 | Dietary management

Involvement of a nutritionist/dietitian with knowledge and experience in nutritional management of youth with diabetes is necessary and experience with the unique characteristics of youth with T2DM is desirable. Dietary recommendations should be culturally appropriate, sensitive to family resources, and should be provided to all caregivers. The family should be encouraged to make dietary changes consistent with healthy eating recommendations, including individualized counseling for weight reduction, reduced carbohydrate and total and saturated fat intake, increased fiber intake, and increased physical activity. More specific dietary recommendations are given in the ISPAD Guidelines for dietary management and by the American Academy of Pediatrics.<sup>79</sup>

### 6.5.1 | Dietary modification should focus on

- Eliminating sugar-sweetened soft drinks and juices. Complete elimination of these drinks and substitution of water and other calorie-free beverages can result in substantial weight loss. FDA-approved nonnutritive sweeteners (NNS) may help patients limit carbohydrate and energy intake,<sup>80</sup> but evidence that NNS can provide sustained reduction in weight or insulin resistance is lacking.
- Increasing fruit and vegetable intake.
- Reducing the use of processed, prepackaged, and convenience foods.
- Reducing the intake of foods made from refined, simple sugars and high fructose corn syrup.
- Portion control.
- Reducing meals eaten away from home.
- Asian diets that primarily consist of high-carbohydrate meals, and in some regions, high animal protein intake, should be modified, with increased portions of fresh vegetables and decreased portions of carbohydrate rich noodles, white rice, and starches.

- Changing staple foods from enriched white rice and white flour to brown rice and whole grain items with lower glycemic index to promote gradual and sustainable absorption with meals.
- Changing family diet behaviors:
  - Limiting availability of high-fat, high-calorie dense food and drink.
  - Teaching families to interpret nutrition fact labels.
  - Emphasizing healthy parenting practices related to diet and activity by promoting parental modeling of healthy eating habits, but avoiding overly restricted food intake.
  - Encouraging positive reinforcement of all goals achieved (eg, no or minimal weight gain, reduction in high caloric drinks) and avoiding blame for failure.
  - Promoting meals eaten on schedule, in one place, preferably as a family unit, and with no other activity (television, computer, studying), and minimizing frequent snacking.
  - Collaboration with the family to consider cultural food preferences and the use of food during family events and cultural festivals.
  - Maintaining food and activity logs as beneficial for raising awareness of food and activity issues and for monitoring progress.

## 6.6 | Exercise management

Exercise is an important part of the diabetes management plan. Regular exercise has been shown to improve blood glucose control, reduce cardiovascular risk factors, contribute to weight loss, and improve well-being<sup>81-83</sup> Youth with T2DM should be encouraged to engage in moderate-to-vigorous exercise for at least 60 minutes daily; this can be completed in several shorter segments. Specific, negotiated, and enjoyable exercise prescriptions should be developed for each patient and family that are sensitive to family resources and environment. A family member or friend should be identified who is available to participate in physical activity with the patient.

Exercise management should include:

- Collaborative development of an achievable daily exercise program to break the entrenched sedentary lifestyle characteristic of youth with T2DM,
- Reduction in sedentary time, including TV, computer-related activities, texting, and video games.<sup>84</sup> Screen time should be limited to less than 2 hours a day. Use of electronic entertainment and communication devices such as video games, computers, and smart phones are associated with shortened sleep duration, excess body weight, poorer diet quality, and lower physical activity levels.<sup>84-86</sup>
- Promotion of stable household routines, particularly increasing sleep duration and reducing TV viewing.<sup>86,87</sup>
- Addressing sedentary time spent doing school work and identifying ways to incorporate physical activity as breaks.
- Promotion of physical activity as a family event, including daily efforts to be physically more active, such as using stairs instead of

elevators, walking or bicycling to school and to shop, and doing house and yard work,

- Encouragement of positive reinforcement of all achievements and avoidance of shaming.

## 6.7 | Smoking and alcohol

While cigarette smoking is harmful to all youth, those with special healthcare needs are especially vulnerable to the negative health consequences of tobacco as a result of their compromised health status and disease, as well as treatment-related complications.<sup>88</sup> Additional research is needed to develop and examine the efficacy of interventions specifically targeting tobacco use among youth with T2DM within healthcare settings. Patients should be asked at each visit if they are smoking and counseled against initiation of smoking. Those youth who are smoking should be counseled on the importance of smoking cessation and provided resources for support. Similarly, the deleterious effects of the misuse of alcohol in the setting of diabetes and risk for fatty liver disease, as well as for hypoglycemia, should be discussed at each visit.

## 6.8 | Glycemic monitoring

- SMBG
  - SMBG should be performed regularly. The frequency of SMBG should be individualized and include a combination of fasting and postprandial glucose measurements with a frequency based on the medication(s) used, the degree of glycemic control present, and available resources. Unlike in T1DM, the evidence that SMBG has an impact on glycemic control in individuals with T2DM is limited.
  - Once glycemic goals have been achieved, limited at home testing is needed and a few fasting and post prandial values a week are generally satisfactory. If values rise out of the target range consistently, more frequent testing should be recommended to identify the possible need for change in therapy.
  - During acute illness or when symptoms of hyper- or hypoglycemia occur, patients should perform more frequent testing and be in contact with their diabetes care team for advice.
  - Patients on insulin or sulfonylureas need to use SMBG more frequently to monitor for asymptomatic hypoglycemia, particularly at night.
  - HbA1c concentration should be determined at least twice a year and quarterly, if possible.
  - The potential benefit of continuous glucose monitoring is being investigated in this population.

## 6.9 | Pharmacologic therapy

The aims of therapy in youth-onset T2DM are to improve glycemia, to prevent acute and chronic complications, to prevent metabolic decompensation, to improve insulin sensitivity, to improve endogenous insulin secretion if possible, to restore glucagon and incretin physiology, and to provide exogenous insulin when necessary. Furthermore, the choice of therapeutic approach should consider the

effect on comorbidities and cardiovascular risk. While many oral hypoglycemic agents are approved for use in adults, only metformin is approved for use in youth in the majority of countries. Sulfonylureas are approved for use in adolescents in some countries; other oral agents are described below for information, recognizing that some adolescents may benefit from their use. However, newer agents are generally more expensive than the core therapies and evidence for their efficacy and safety in youth is limited or currently non-existent. Many clinical trials of anti-hyperglycemic agents are underway in youth-onset T2DM, but recruitment is slow and results are not expected for a few more years.

### 6.9.1 | Initial treatment

Initial treatment of youth with T2DM should include metformin and/or insulin alone or in combination. The specifics of the initial treatment modality are determined by symptoms, severity of hyperglycemia, and presence or absence of ketosis/ketoacidosis. As in T1DM, those with symptoms, particularly vomiting, can deteriorate rapidly and need urgent assessment and treatment.

1. If the patient is metabolically stable—HbA1c < 8.5% (69.4 mmol/mol) and no symptoms—metformin is the treatment of choice together with healthy lifestyle changes. Begin with 500 to 1000 mg daily  $\times$  7 to 14 days. Titrate by 500 to 1000 mg every 1 to 2 weeks, depending on patient tolerability, over 3 to 4 weeks until the maximal dose of 1000 mg BID, 850 mg TID (or 2000 mg once a day of extended-release metformin where available) is reached.
2. In patients with ketosis/ketonuria/ketoacidosis or HbA1c > 8.5% (69.4 mmol/mol), insulin will be required initially. A variety of insulin regimens are effective, but once-a-day intermediate or basal insulin (0.25–0.5 units/kg starting dose) is often effective in attaining metabolic control, while entailing minimal patient burden and being well-tolerated by the patients. The primary adverse effect of insulin is weight gain. The risk of hypoglycemia should also be considered, but is uncommon in adolescents with T2DM due to their insulin resistance. Metformin can generally be started at the same time as insulin, unless acidosis is present.
3. Transition onto metformin can usually be achieved over 2 to 6 weeks by decreasing the insulin dose 30% to 50% each time the metformin is increased, with a goal of eliminating insulin therapy if this can be achieved without loss of glycemic control. Data from the TODAY study indicate that 90% of youth with T2DM can be successfully weaned off insulin and treated with metformin alone.<sup>38,39</sup>

### 6.9.2 | Subsequent therapy

The goal of initial treatment should be to attain an HbA1c of less than 7.0% (53 mmol/mol),<sup>89</sup> and in some situations <6.5% (47.5 mmol/mol).<sup>90</sup> This can almost always be accomplished with metformin and basal insulin, alone or in combination. Long-term glycemic control is more likely when therapy is intensified to maintain the HbA1c target (treat-to-target) rather than waiting for the HbA1c to rise before intensifying therapy (treat-to-failure).<sup>91</sup>



- If the patient fails to reach target HbA1c of <7.0% (53 mmol/mol) or <6.5% (47.5 mmol/mol) within 4 months on metformin monotherapy, addition of basal insulin should be considered.
- If target is not attained on combination metformin and basal (up to 1.5 U/kg/day), initiation of prandial insulin should be considered, with titration to reach target HbA1c < 7.0% (53 mmol/mol) or <6.5% (47.5 mmol/mol).
- Use of other oral or injected agents known to be effective in adults with T2DM for youth with T2DM may be beneficial in addition to, or instead of, metformin and insulin, but there are limited studies of the use of these agents and they are generally approved only for patients >18 years of age. These agents have not been specifically studied in young adults between 18 and 25 years, but it is presumed their safety and effectiveness are similar to that reported for older adults.

## 6.10 | Metformin

Metformin acts through AMP kinase in liver, muscle, and fat and improves glycemia through reducing hepatic glucose production by decreasing gluconeogenesis, and by stimulating peripheral glucose uptake in some but not all studies. Additionally, an initial anorexic effect may promote limited and likely unsustainable weight loss.

- There is little to no risk of hypoglycemia with monotherapy.
- Intestinal side effects (transient abdominal pain, diarrhea, nausea) may occur, but can be minimized in most patients with slow dosage titration over 3 to 4 weeks and instructions to always take the medication with food. The side effects may also be attenuated by the use of extended release formulations.
- The risk of lactic acidosis with metformin is extremely low. Metformin should not be given to patients in ketoacidosis, with renal impairment, cardiac or respiratory insufficiency, or who are receiving radiographic contrast materials. Metformin should be temporarily discontinued during a gastrointestinal illness.<sup>89</sup>
- Metformin may normalize ovulatory abnormalities in girls with polycystic ovary syndrome (PCOS) (ovarian hyperandrogenism) and increase pregnancy risk.<sup>92</sup>
- Metformin is approved for use during pregnancy.
- Recent studies in adults indicate increased prevalence of B12 deficiency in adults taking metformin, but the implications for adolescents are unclear; no cases of B12 deficiency were reported in the TODAY study.<sup>93</sup> Nevertheless, periodic monitoring of B12 should be considered.

## 6.11 | Other available agents

### 6.11.1 | Sulfonylurea and meglitinides (not approved for use in those <18 years in all countries)

These agents bind to receptors on the K<sup>+</sup>/ATP channel complex causing K<sup>+</sup> channels to close, resulting in insulin secretion. Meglitinides bind to a separate site from sulfonylureas on the K<sup>+</sup>/ATP channel complex. Sulfonylurea sites equilibrate slowly and binding persists for prolonged periods; thus, traditional sulfonylureas have prolonged effects. Meglitinides<sup>94</sup> have an intermediate equilibration and binding

duration and are prescribed for rapid enhancement of insulin secretion before meals. Overall, use of sulfonylureas in adults is associated with a 1.5% to 2% decrease in HbA1c.

- The major adverse effects of sulfonylureas are:
  - Hypoglycemia: may be severe and prolonged depending on the agent used
  - Weight gain
- There has been a single pediatric clinical trial of a sulfonylurea (glimpiride), which showed no superior efficacy to metformin and a greater degree of weight gain and hypoglycemia.<sup>95</sup>
- Sulfonylureas may accelerate the loss of beta-cell function and eventual loss of control on oral therapy alone.<sup>96</sup>

### 6.11.2 | Thiazolidinedione (TZD) (not approved for use in those <18 years of age)

TZDs bind to nuclear peroxisome proliferator activator receptors (PPAR gamma), which are ubiquitous orphan steroid receptors particularly abundant in adipocytes. These agents increase insulin sensitivity in muscle, adipose, and liver tissue, with a greater effect on muscle glucose uptake than biguanides. Long-term treatment in adults is associated with a reduction in HbA1c of 0.5% to 1.3%. The side effects of TZDs include weight gain, anemia, fluid retention (including congestive heart failure),<sup>94,97</sup> and possible association with bladder cancer.<sup>98</sup> Liver toxicity associated with earlier members of this family have not been found with the newer TZDs. Rosiglitazone was under substantial marketing restriction in the United States and Europe due to concerns for an increased risk for congestive heart failure and myocardial infarction. Although these restrictions have been lifted, the future of TZDs in therapy for T2DM in adults or youth remains unclear.

In the TODAY study, therapeutic failure rates were the lowest in the group receiving metformin plus rosiglitazone (38.6%) vs metformin alone (51.7%) vs metformin plus lifestyle (46.6%).<sup>17</sup> Thus, addition of rosiglitazone to metformin decreased the risk for progression to insulin requirement by 23%.

### 6.11.3 | $\alpha$ -Glucosidase inhibitors (not approved for use in those <18 years of age)

$\alpha$ -glucosidase inhibitors (acarbose, miglitol) reduce the absorption of carbohydrates in the upper small intestine by inhibiting breakdown of oligosaccharides, thereby delaying absorption in the lower small intestine. This reduces the postprandial rise of plasma glucose. Long-term therapy is associated with 0.5% to 1% (5.5-10.9 mmol/mol) reduction in HbA1c. Because of their mechanism of action, these agents have been particularly widely used and successful in countries where carbohydrates make up a substantial part of the diet.<sup>99</sup> There have been no trials of  $\alpha$ -glucosidase inhibitors in youth, but the frequent side effect of flatulence makes these agents unattractive to most adolescents.

### 6.11.4 | Incretin mimetics (glucagon-like peptide-1 [GLP-1] receptor agonists) (not approved for use in those <18 years of age)

GLP-1 is secreted by L-cells in the small intestine in response to food, increasing insulin secretion proportionate to BG concentrations,

suppressing glucagon, prolonging gastric emptying, and promoting satiety. They are rapidly degraded by dipeptidyl peptidase-IV (DPP-IV); both native GLP-1 and the injected mimetic have a serum half-life of 2 minutes. However, pharmaceutical alterations in the GLP-1 agonists have resulted in longer-acting injected agents given twice-daily, once daily, or once-weekly subcutaneous injections. Clinical trials in adults have shown reduced fasting and post-prandial BG, weight loss, and lower HbA1c (0.5%-0.8%), as well as reduction in cardiovascular and renal events in high-risk patients.<sup>100,101</sup> Adverse effects include nausea, vomiting, diarrhea, and infrequent dizziness, headache, and dyspepsia. The side effects generally decrease over time. Besides a single publication of the pharmacodynamics and the pharmacokinetics of liraglutide in adolescents with T2DM,<sup>102</sup> there are no published studies of efficacy and safety of incretin mimetics in youth T2D, but several are currently underway.

#### 6.11.5 | DPP-IV Inhibitors (not approved for use in those <18 years of age)

DPP-IV inhibitors inhibit the enzyme that breaks down GLP-1, resulting in higher concentrations of GLP-1 and effects similar to those of GLP-1 mimetics, though unlike GLP-1 mimetics, they have no effect on gastric emptying, satiety or weight loss. DPP-IV inhibitors are administered orally once or twice daily and long-term therapy in adults is associated with 0.5% (5.5 mmol/mol) reduction in HbA1c. There have been no published studies of DPP-IV inhibitors in youth, but several are currently underway.

#### 6.11.6 | Sodium-Glucose Co-transporter 2 (SGLT2) inhibitors (not approved for use in those <18 years of age)

SGLT-2 inhibitors inhibit renal tubular reabsorption of glucose, leading to increased urinary glucose loss, reduction in serum glucose, and weight loss. The use of SGLT 2 inhibitors in adults is associated with reduction in HbA1c approaching that seen with metformin.<sup>91</sup> Furthermore, SGLT2 inhibitors have been shown to have beneficial effects on weight loss, BP, renal function, and cardiovascular outcomes in adults.<sup>103-106</sup> Adverse effects include small increases in prevalence of genitourinary infections, particularly among women and uncircumcised men.<sup>107</sup> Canagliflozin has been associated with increased rates of lower extremity amputations in adults at risk for vascular compromise<sup>108</sup> and there have been reports of euglycemic diabetic ketoacidosis in patients on SGLT2 inhibitors.<sup>109</sup> There have been no studies of SGLT2 inhibitors in youth, but several are currently underway.

### 6.12 | Gastric surgery

Bariatric surgery may be considered for adolescents with obesity-related comorbidities, including T2DM, particularly when patients have been unsuccessful with medical therapy alone. Recent results from a large US consortium of pediatric bariatric surgery centers has demonstrated remission of T2DM and other comorbidities in nearly all youth, with attainment of HbA1c targets exceeding that seen with medical therapy.<sup>110,111</sup> Currently metabolic surgery is considered for adolescents with T2DM and BMI > 35 kg/m<sup>2</sup> who have uncontrolled glycemia and/or comorbidities despite lifestyle and pharmacologic treatment. Although the morbidity and mortality rates in adults have

decreased over the last 5 years, this treatment should be undertaken only in centers of excellence with an established and experienced surgical, nutritional, behavioral, and medical support and outcome data collection program.

## 7 | T2DM AND INSULIN RESISTANCE: COMORBIDITIES AND COMPLICATIONS

Insulin resistance is a physiologic abnormality, defined as an impaired response to the physiologic effects of insulin, including effects on glucose, lipid, and protein metabolism, and on vascular endothelial function. Insulin resistance is increased during mid-puberty, pregnancy, aging, and the luteal phase of the menstrual cycle, in individuals of some ethnicities, and in those with increased total and visceral adiposity, high fat diet, and sedentary behavior.

Several events in development may be associated with increased risk for the insulin resistance syndrome, including premature adrenarche,<sup>112</sup> being born small for gestational age (SGA) or to a pregnancy complicated by maternal obesity.<sup>113</sup> The development of obesity and inactivity during childhood also increases the likelihood of insulin resistance.

The insulin resistance syndrome is a collection of abnormalities that are increased in prevalence in insulin-resistant individuals. These abnormalities include:

- Dysglycemia (IFG, IGT, T2DM)
- Lipid abnormalities (increased triglycerides, decreased HDL-C, small, dense LDL-C particles)
- Endothelial dysfunction (increased mononuclear cell adhesion, plasma cellular adhesion molecules, decreased endothelial-dependent vasodilatation)
- Increased procoagulant factors (plasminogen activator inhibitor-1 and fibrinogen)
- Hemodynamic changes (increased sympathetic nervous system activity, increased renal sodium retention)
- Inflammation (increased C-reactive protein, cytokines.)
- Increased plasma uric acid
- Increased hepatic and intramyocellular lipid deposition
- Mitochondrial dysfunction
- Ovarian hyperandrogenism
- Sleep-disordered breathing.

Because of these insulin resistance-related abnormalities, individuals with insulin resistance have a higher risk of developing overt T2DM, cardiovascular disease, hypertension, polycystic ovary syndrome, NAFLD, nephropathy, OSA, and some types of cancer. In contrast to the definition of metabolic syndrome (MetS) in adults,<sup>114</sup> there is no standard definition of metabolic syndrome for use in the pediatric population and more than 46 different pediatric metabolic syndrome definitions have been used.<sup>115,116</sup> Indeed, the concept of defining the MetS in childhood has been criticized due to absence of epidemiologic data associated any definition with cardiovascular risk.<sup>117</sup> In 2007, the International Diabetes Federation published its definition of the MetS in children and adolescents based on

extrapolation from adult data.<sup>118</sup> This panel recommended the following criteria:

1. for children 6 to <10 years old, obesity (defined as  $\geq 90$ th percentile of waist circumference), followed by further measurements as indicated by family history;
2. for age 10 to <16 years, obesity (defined as waist circumference  $\geq 90$ th percentile), followed by the adult criteria for triglycerides, HDL-C, BP, and glucose. For youth  $\geq 16$  years of age, the panel recommends using the existing International Diabetes Federation criteria for adults.

When this definition is used, MetS is rapidly increasing in prevalence with rising childhood obesity and sedentary lifestyles worldwide. In western countries, the incidence of childhood obesity has more than doubled over the past generation. Studies show that the prevalence of metabolic syndrome in obese youth ranges from 19% to 35%, compared with <2% in normal-weight groups. The odds of developing metabolic syndrome in obese boys and girls were 46-67 and 19-22 times greater, respectively, than for normal-weight youth.<sup>119</sup> A recent study showed that the prevalence of metabolic syndrome was 27.6% in obese Chinese children, compared to 0.2% in normal weight children.<sup>120</sup> Similar findings have been reported from India.<sup>121</sup>

Co-morbidities characteristic of insulin resistance are commonly present at diagnosis or appear early in the course of T2DM and should be screened for sooner than in T1DM, where these disorders are generally seen as complications of long-standing diabetes rather than as co-morbid conditions.<sup>122</sup> A more complete discussion of screening for complications/co-morbidities is presented in the ISPAD Guidelines for microvascular, macrovascular, and other complications.<sup>123,124</sup>

## 7.1 | Obesity

Obesity has deleterious associations with morbidity independent of insulin resistance and diabetes.<sup>125-127</sup> In addition, weight loss and exercise both improve insulin resistance and glycemia. Shifts up or down in BMI category during childhood are associated with increases and decreases in cardiovascular risks markers.<sup>128</sup> Therefore, assessment of BMI and pattern of weight gain should be considered a routine part of monitoring in youth with T2DM.<sup>129</sup>

## 7.2 | Hypertension

Hypertension is associated with endothelial dysfunction, arterial stiffness, and increased risk of both cardiovascular and kidney disease.<sup>130</sup> Moreover, tight BP control in adults with T2DM in the UK Prospective Diabetes Study (UKPDS) improved microvascular and macrovascular disease at least as much as control of glycemia.<sup>131</sup> Hypertension was present in 13.6% of 699 US youth in the TODAY study at a median duration of diabetes of 7 months,<sup>26</sup> progressing to 33.8% during average follow-up 3.9 years.<sup>18</sup> Male sex and higher BMI significantly increased the risk for hypertension in the TODAY cohort. Eppens et al.<sup>132</sup> reported even higher rates in Australia, with 36% of youth with T2DM having hypertension within 1.3 years of T2DM

diagnosis. Moreover, the SEARCH Study, which included US youth with longer diabetes duration, found hypertension in 65% of youth with T2DM.<sup>133</sup> Hypertension in T2DM is related to renal sodium retention and resulting volume expansion, increased vascular resistance related to reduced nitric-oxide-mediated vasodilatation, and increased sympathetic stimulation by hyperinsulinemia. In addition, there is a possible genetic predisposition to hypertension in T2DM related to associated increased activity of the renin-angiotensin system.

- BP should be measured with an appropriate-sized cuff at every clinic visit, and values compared to the normal ranges for sex, height and age.
- Initial treatment of BP consistently at, or above, the 95th percentile on three occasions should consist of efforts at weight loss, limitation of dietary salt, and increased physical activity.
- If, after 6 months, BP is still above the 95th percentile, initiation of an ACE inhibitor or ARB should be considered to achieve BP values that are less than the 90th percentile.<sup>134,78,130,135</sup> If the ACE inhibitor is not tolerated due to adverse effects (mainly cough), an ARB, calcium channel blocker, or diuretic are alternatives.
- Combination therapy may be required if hypertension does not normalize on single agent therapy. However, combination ACE inhibitor and ARB are not recommended due to an excess of adverse events and no added clinical benefit.<sup>136</sup> Evaluation of hypertension not responsive to initial medical therapy should also include a renal ultrasound and echocardiogram.<sup>130</sup>

## 7.3 | Nephropathy

Albuminuria (either micro- or macro-) is present at the time of diagnosis in a substantial number of adolescents with T2DM and prevalence increases with duration of diabetes. In the TODAY study, microalbuminuria was found in 6.3% of 699 T2DM youth at baseline at a median disease duration of 7 months and prevalence rose to 16.6% by 36 months<sup>18,26</sup>; higher levels of HbA1c were significantly related to risk of developing microalbuminuria. Similar findings have been reported in smaller studies of US minority and Indian, Canadian First Nation and Maori youth<sup>70,137,138</sup> and macroalbuminuria was reported in 16% of First Nation youth after relatively short disease duration.<sup>139</sup> In a study in Manitoba, Canada, youth with microalbuminuria were nine times as likely to develop renal failure as those without microalbuminuria.<sup>140</sup> Thus, the presence of albuminuria in youth was highly predictive of the future risk of renal failure. The prevalence of micro- and macroalbuminuria is higher and the progression of nephropathy is accelerated in youth-onset T2DM compared to T1DM in all populations examined. In a Japanese cohort of 1065 patients diagnosed with T2DM prior to age 30 years, 31 (3%) developed renal failure requiring dialysis at a mean age of 35 years. Factors influencing progression were diabetes duration, HbA1c, and diastolic BP. Moreover, the incidence of nephropathy for those diagnosed age 10 to 19 years was double that of individuals in the same population with T1DM, even when accounting for duration of disease.<sup>141</sup>

- Albuminuria should be evaluated at diagnosis and annually thereafter
- The definition of microalbuminuria used by the ADA is either:
  - Albumin-to-creatinine ratio 30 to 299 mg/g (3.39–33.79 mg/mmol) in a spot urine sample (preferred)
  - Timed overnight or 24-hour collections with albumin excretion rate of 20 to 199 mcg/min.
- An elevated value can be secondary to exercise, smoking, menstruation and orthostasis. Therefore, the diagnosis of persistent abnormal microalbumin excretion requires documentation of two of three consecutive abnormal values obtained on different days.
  - Repeat testing should be done in the AM immediately after rising, as orthostatic proteinuria is common in adolescents and is considered benign.
- Non-diabetes-related causes of renal disease should be considered and consultation with a nephrologist obtained if macroalbuminuria (ACR > 300 mg/g) is present.
- If urine ACR is confirmed to be >30 mg/g (3.39 mg/mmol) and BP is elevated, or if urine ACR is >300 mg/g (33.9 mg/mmol) irrespective of BP, ACE inhibitor or ARB should be started and BP normalized (A)
- A repeat lipid profile should be performed in 6 months.
- If repeat LDL-C > 130 mg/dL (>3.4 mmol/L): begin medication with a goal of <130 mg/dL (<3.4 mmol/L) and an ideal target of <100 mg/dL (<2.6 mmol/L).
- Statin therapy has been shown to be safe and effective in children as in adults and should be the first pharmacologic intervention,<sup>123</sup> although long term safety data are not available.
- Statin treatment should begin at the lowest available dose and dose increases should be based on monitoring of LDL-C levels and side effects.
- The use of statins in sexually active adolescent females must be carefully considered and the risks explicitly discussed, as these drugs are potentially teratogenic and not approved in pregnancy.
- Routine monitoring of liver enzymes is not required with statin therapy.
- Elevated triglycerides can increase the risk for pancreatitis.
  - If the triglycerides are >150 mg/dL (>1.7 mmol/L), efforts to maximize blood glucose control, limit dietary fat and simple sugars and achieve desirable weight should be emphasized.
  - If fasting triglycerides are >400 mg/dL (5.6 mmol/L) or non-fasting triglycerides >1000 mg/dL (11.3 mmol/L) treatment with a fibric acid should be considered due to significantly increased risk for pancreatitis, with a goal of <150 mg/dL (<1.7 mmol/L).
- Low HDL-C levels in youth are not managed directly with medication, but physical activity and healthy diet should be encouraged.

## 7.4 | Dyslipidemia

Hypertriglyceridemia and decreased HDL-C are the hallmarks of the dyslipidemia characteristic of obesity, insulin resistance and T2D. In the TODAY study, 79.8% of T2DM youth had a low HDL-C and 10.2% had high triglycerides within a few months of diagnosis<sup>26</sup> and the SEARCH study found that 73% of 2096 US youth with T2DM of longer duration had a low HDL and 60% to 65% had hypertriglyceridemia.<sup>142</sup> In a Canadian First Nations population of 99 youth with T2DM, total cholesterol, LDL-C, triglycerides and apoB level greater than the National Health And Nutritional Evaluation Study (NHANES) 75th percentile were found in 60%, 41%, 43%, and 43%, respectively, and low HDL-C in 35%.<sup>139</sup> In 68 Australian youth with a duration of T2DM of less than 3 years, elevated total cholesterol was found in 32% and hypertriglyceridemia in 53%.<sup>132</sup> Finally in Taiwan, hypercholesterolemia was present in 27% youth with T2DM.<sup>7</sup> Additional findings include elevated VLDL, elevated Lp<sub>a</sub>, and increased small dense LDL-C particles. Decreased lipoprotein lipase activity, increased lipoprotein allocation and increased lipoprotein oxidation render the lipoproteins more atherogenic.

- In youth with T2DM, testing for dyslipidemia should be assessed once glycemic control has been achieved or after 3 months of initiation of medication, and annually thereafter.<sup>78,130</sup> Initial screening does not need to be done fasting.
- Goal levels are:
  - LDL-C < 100 mg/dL (<2.6 mmol)
  - HDL-C > 35 mg/dL (0.91 mmol/L)
  - triglycerides <150 mg/dL (1.7 mmol/L)
- If LDL-C is above goal,
  - blood glucose control should be maximized and dietary counseling should be provided (7% saturated fat, <200 mg cholesterol) and exercise encouraged.<sup>130</sup>

## 7.5 | Atherosclerosis and vascular dysfunction

Hyperglycemia, dyslipidemia, and hypertension are contributors to the acceleration of atherosclerosis in T2D, along with oxidative stress, glycation of vascular proteins, and abnormalities in platelet function and coagulation. Defective endothelium-dependent vasodilatation is an additional factor accelerating atherosclerosis in T2DM. Endothelial dysfunction is an early sign of increased risk for cardiovascular disease, is predictive of cardiovascular events and occurs in obese children relative to their level of obesity and degree of insulin resistance.<sup>143,144</sup> In addition, youth with T2DM have increased intima media thickness, serum markers of endothelial damage, left ventricular hypertrophy,<sup>145,146</sup> cardiac dysfunction, reduced maximal exercise capacity<sup>55</sup> and increased arterial stiffness,<sup>147</sup> all of which predict early cardiovascular morbidity and mortality.

## 7.6 | Polycystic ovary syndrome (PCOS)

PCOS is increasingly recognized in adolescent girls with obesity. Adolescents with PCOS have ~40% reduction in insulin-stimulated glucose disposal compared to body composition matched non-hyperandrogenic control subjects.<sup>148</sup> There are limited data on the exact prevalence of PCOS in youth with T2DM, but a study of 157 adult women of reproductive age with T2DM found the PCOS prevalence to be high at 8.3%.<sup>149</sup> A lack of periods can increase long term risk of endometrial cancer and PCOS increases lifetime risk for cardiovascular disease.<sup>150</sup>

- A menstrual history should be taken on every girl with T2DM at diagnosis and at each visit.
- An evaluation for PCOS should be considered if there is primary or secondary amenorrhea, hirsutism and or significant acne.
- PCOS is diagnosed based on the presence of oligo- or amenorrhea with biochemical or clinical evidence of hyperandrogenism, without or without evidence for polycystic ovaries.<sup>92</sup>
- Decreasing insulin resistance with weight loss, exercise and metformin improves ovarian function and increases fertility.
- Girls receiving diabetes treatment should also be counseled that fertility may improve as a result and appropriate birth control should be used when desired to prevent pregnancy.

## 7.7 | Non-alcoholic fatty liver disease

Hepatic steatosis is present in 25% to 50% of adolescents with T2DM and more advanced forms of NAFLD, such as NASH, are increasingly common and associated with progression to cirrhosis, portal hypertension, and liver failure.<sup>151,152</sup> NAFLD is the most frequent cause of chronic liver disorders among obese youth<sup>153</sup> and is the most common reason for liver transplantation in adults in the United States. In the United States, Hispanics have the highest prevalence of NAFLD, followed by non-Hispanic Whites, while the prevalence among African-American is much lower.<sup>154</sup> However, these prevalence estimates are based on liver enzyme elevations and are likely an underestimate of the prevalence of hepatic steatosis in T2DM youth, as steatosis is more common than elevated liver enzymes and liver enzymes can be normal despite having steatosis.<sup>155</sup> Newer imaging methods for analysis of liver fat and inflammation are emerging and may become more standard in coming years.<sup>156</sup> Presence of the metabolic syndrome in obese adolescents predicts IGT and NAFLD<sup>55</sup> and the presence of T2DM independently predicts progression to fibrosis.<sup>157</sup>

Weight loss improves NAFLD and metformin has been shown to improve liver enzymes and liver steatosis in youth in insulin resistant adolescents.<sup>55,158</sup> In the TODAY study, permanent medication reductions/discontinuation due to elevated liver enzymes was lowest in the metformin plus rosiglitazone group.<sup>93</sup> Thus, T2DM therapies that improve insulin resistance appear to improve NAFLD and, therefore, are the standard approach to youth with both NAFLD and T2DM. However, due to the potential for progression to NASH, fibrosis and cirrhosis, ongoing monitoring of liver enzymes is recommended in youth with T2DM, with referral for imaging and/or biopsy if enzymes remain >3 times ULN despite weight loss and/or diabetes therapies.

## 7.8 | Obstructive sleep apnea

OSA is common in obese youth, but the prevalence in pediatric T2DM has not yet been well documented. However, it is likely high, since the prevalence of OSA in adults with T2DM is between 70% and 90%.<sup>159,160</sup> OSA not only causes poor sleep quality and daytime sleepiness, but in adults it has clinical consequences, including hypertension, left ventricular hypertrophy and increased risk of renal and cardiovascular disease.

- The International Diabetes Federation Taskforce on Epidemiology and Prevention strongly recommended that health professionals working in adult T2DM consider the presence of OSA.<sup>161</sup>
- OSA can be screened for in youth with T2DM using questions about snoring, sleep quality, apnea, morning headaches, daytime sleepiness, nocturia, and enuresis.
- If symptoms are suggestive, the diagnosis of OSA is made by formal sleep study and referral to a sleep specialist.

## 7.9 | Depression, anxiety, eating disorders, cognition

Youth with T2DM are at increased risk for a number of major mental health challenges, including major clinical depression,<sup>162-165</sup> which is associated with poor adherence to diabetic treatment recommendations.<sup>162,164,166</sup> Current evidence suggests the early presence of depressive symptomatology, higher distress scores and anxiety, equivalent to or greater than that seen in T1DM and older onset T2DM.<sup>167</sup> Signs include depressed mood, markedly diminished interest or pleasure, increased or decreased appetite, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue or loss of energy, feelings of worthlessness and recurrent thoughts of death.

- Youth with T2DM should be assessed for depression at diagnosis and periodically thereafter, particularly in those with frequent emergency department visits or poor glycemic control.
- Identified patients should be referred to appropriate mental health care providers experienced in addressing depression in youth.<sup>162</sup>

There is also increasing evidence of a high prevalence of anxiety disorders, eating disorders,<sup>168,169</sup> social isolation and impaired cognitive function in youth with T2DM and their caregivers.<sup>170</sup> The assessment and treatment of these disorders should be considered part of the comprehensive care of youth with T2DM.

## 7.10 | Cardiovascular risk in youth-onset T2D

Adults in their 40s with youth-onset T2DM have a marked excess of macrovascular disease, with a high prevalence of ischemic heart disease (12.6%), stroke (4.3%), the composite end point of any macrovascular disease (14.4%) and death (11%).<sup>24</sup> In addition, these endpoints were markedly higher than a similarly aged group of participants with T1DM, despite similar glycemic control and a longer duration of diabetes in the T1DM group. It has been estimated that youth and young adults with T2DM lose approximately 15 years from average life expectancy and may experience severe, chronic complications by their 40s.<sup>171</sup> Furthermore, emerging evidence suggests that early onset of T2DM may be associated with more aggressive development of microvascular and macrovascular complications than T2DM appearing at later ages.<sup>21,172-174</sup> Therefore, a comprehensive management plan that includes early and aggressive control of diabetes complications and cardiovascular risk factors is needed to reduce lifetime risk of morbidity and early death. This risk for accelerated cardiovascular disease in young adults argues for transition of these patients to multi-disciplinary adult medical providers who can provide expertise in

comprehensive monitoring and treatment of diabetes and related complications.

## 8 | POPULATION SCREENING FOR T2DM IN HIGH-RISK YOUTH

As opposed to identification of diabetes in a specific youth in whom there is a moderate or high level of clinical suspicion for diabetes, screening refers to broad based testing of a population or testing of individuals meeting certain general criteria. While the former is necessary in the evaluation of individual patients, the latter is only justifiable in certain circumstances.<sup>175</sup> General guidelines to justify a screening test and as applied to T2DM in youth are as follows:

- The condition tested for is sufficiently common to justify the cost of the testing.
  - It is not clear that this is the case in most populations. In the United States, screening based on fasting and post-challenge glucose in high-risk minority adolescents at the peak age of T2DM diagnosis identified <1% with T2DM.<sup>176</sup> Whether there is sufficient prevalence of undiagnosed T2DM in specific populations of adolescents to justify testing remains unclear.
  - If the disorder has low prevalence, most abnormal tests will be false positives and require additional testing, which must be included in the determination of cost.
- The condition tested for is serious in terms of morbidity and mortality.
  - Unquestionably true of T2DM in adolescents because of the association with increased cardiovascular risk factors and renal dysfunction.
- The condition tested for has a prolonged latency period without symptoms, during which abnormality can be detected and treatment can prevent morbidity.
  - Early detection of T2DM is likely associated with better outcome, though specific published support for this presumption is lacking in youth.
  - Pre-diabetes has been identified in at-risk youth, but there is currently no evidence-based interventions beyond those which would be delivered to the at-risk youth anyway (weight loss, exercise, diet change).
  - Hypertension, dyslipidemia, and microalbuminuria have been identified in youth with pre-diabetes, but also in obese youth without diabetes. Therefore, there is an argument for monitoring and appropriate treatment of hypertension, dyslipidemia, and microalbuminuria in at-risk youth, rather than focusing on identification of dysglycemia.
- A test is available that is sensitive (few false negatives) and accurate with acceptable specificity (minimal number of false positives).
  - None of the currently available tests (fasting glucose, random glucose, 2-hour post-challenge glucose, HbA1c) are sufficiently sensitive and specific to function well given the low prevalence of T2DM, even in high-risk populations

- There remains substantial uncertainty in the normal ranges and meaning of abnormal values in each of these measures of glycemia in youth.

Guidelines issued by the ADA in 2000,<sup>177</sup> the American Academy of Pediatrics in 2013<sup>78</sup> and by the Endocrine Society in 2017<sup>129</sup> all recommend screening for diabetes in the clinical setting in at-risk obese youth after age 10. However, accumulating data indicate that screening to identify diabetes in asymptomatic youth has a low yield and further research is required to determine the optimal strategy for testing, including the frequency of testing. Therefore, for now, the best evidence suggests that population screening for T2DM outside of research settings is not cost-effective in most populations. Urinary glucose screening of youth in Japan and Taiwan may be evidence-based exceptions.<sup>178,179</sup>

## 9 | SUMMARY AND CONCLUSIONS

Youth-onset T2DM has emerged as an important health problem in youth, disproportionately affecting socioeconomic minorities in North America and Europe and increasingly prevalent in emerging economies, such as India, China, Malaysia, and parts of South America. Since the last set of ISPAD guidelines in 2014, there has been substantial progress in our understanding of the disorder and growing recognition that youth-onset T2DM, while sharing aspects of pathophysiology with T2DM occurring later in life, also has important unique features - rapid onset and progression, highly prevalent and rapidly progressing comorbidities, challenging socioeconomic features in most countries, and close association with puberty, a life-stage during which management of chronic disease is especially difficult. Furthermore, youth-onset T2DM has more rapid development of complications and cardiovascular risk than either youth-onset T1D M or adult-onset T2DM, leading to higher morbidity and mortality rates.

Unfortunately, this elevated risk for poor outcome is not always appreciated by families, primary care providers, or diabetes specialists, for whom familiarity with adult onset T2DM and the lack of insulin dependence may generate a false complacency. These features combine to make youth-onset T2DM a particularly challenging disorder and suggest that, given the complex needs of youth with T2DM, such patients should be managed by diabetes providers experienced in the disorder and its associated comorbidities and, where possible, in specialized multi-disciplinary centers. Furthermore, transition to adult care is period of high-risk for worsening of control and adherence and loss of follow-up and should be undertaken thoughtfully.

## REFERENCES

1. Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012. *N Engl J Med.* 2017;376(15):1419-1429.
2. Nadeau KJ, Anderson BJ, Berg EG, et al. Youth-onset type 2 diabetes consensus report: current status, challenges, and priorities. *Diabetes Care.* 2016;39(9):1635-1642.
3. Duncan GE. Prevalence of diabetes and impaired fasting glucose levels among US adolescents: National Health and nutrition examination survey, 1999-2002. *Arch Pediatr Adolesc Med.* 2006;160(5): 523-528.

4. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. *J Pediatr*. 2005;146(5):693-700.
5. Kitagawa T, Owada M, Urakami T, Yamauchi K. Increased incidence of non-insulin dependent diabetes mellitus among Japanese school-children correlates with an increased intake of animal protein and fat. *Clin Pediatr (Phila)*. 1998;37(2):111-115.
6. Ehtisham S, Hattersley AT, Dunger DB, Barrett TG, British Society for Paediatric Endocrinology and Diabetes Clinical Trials Group. First UK survey of paediatric type 2 diabetes and MODY. *Arch Dis Child*. 2004;89(6):526-529.
7. Wei JN, Sung FC, Li CY, et al. Low birth weight and high birth weight infants are both at an increased risk to have type 2 diabetes among schoolchildren in Taiwan. *Diabetes Care*. 2003;26(2):343-348.
8. Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V. Type 2 diabetes in Asian-Indian urban children. *Diabetes Care*. 2003;26(4):1022-1025.
9. Eppens MC, Craig ME, Jones TW, et al. Type 2 diabetes in youth from the Western Pacific region: glycaemic control, diabetes care and complications. *Curr Med Res Opin*. 2006;22(5):1013-1020.
10. Sugihara S, Sasaki N, Kohno H, et al. Survey of current medical treatments for childhood-onset type 2 diabetes mellitus in Japan. *Clin Pediatr Endocrinol*. 2005;14(2):65-75.
11. Fu JF, Liang L, Gong CX, et al. Status and trends of diabetes in Chinese children: analysis of data from 14 medical centers. *World J Pediatr*. 2013;9(2):127-134.
12. Ye Q, Fu JF. Paediatric type 2 diabetes in China-Pandemic, progression, and potential solutions. *Pediatr Diabetes*. 2018;19(1):27-35.
13. Zeitler P, Fu J, Tandon N, et al. ISPAD Clinical Practice Consensus Guidelines 2014. Type 2 diabetes in the child and adolescent. *Pediatr Diabetes*. 2014;15(suppl 20):26-46.
14. Druet C, Tubiana-Rufi N, Chevenne D, Rigal O, Polak M, Levy-Marchal C. Characterization of insulin secretion and resistance in type 2 diabetes of adolescents. *J Clin Endocrinol Metab*. 2006;91(2):401-404.
15. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet*. 1998;352(9131):837-853.
16. Gungor N, Bacha F, Saad R, Janosky J, Arslanian S. Youth type 2 diabetes: insulin resistance, beta-cell failure, or both? *Diabetes Care*. 2005;28(3):638-644.
17. TODAY Study Group, Zeitler P, Hirst K, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. *N Engl J Med*. 2012;366(24):2247-2256.
18. TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. *Diabetes Care*. 2013;36(6):1735-1741.
19. TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and beta-cell function in TODAY. *Diabetes Care*. 2013;36(6):1749-1757.
20. Bacha F, Gungor N, Lee S, Arslanian SA. Progressive deterioration of beta-cell function in obese youth with type 2 diabetes. *Pediatr Diabetes*. 2013;14(2):106-111.
21. Gandica R, Zeitler P. Update on youth-onset type 2 diabetes: lessons learned from the treatment options for type 2 diabetes in adolescents and youth clinical trial. *Adv Pediatr*. 2016;63(1):195-209.
22. Dabelea D, Stafford JM, Mayer-Davis EJ, et al. Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood. *JAMA*. 2017;317(8):825-835.
23. Dyck RF, Jiang Y, Osgood ND. The long-term risks of end stage renal disease and mortality among first nations and non-first nations people with youth-onset diabetes. *Can J Diabetes*. 2014;38(4):237-243.
24. Constantino MI, Molyneaux L, Limacher-Gisler F, et al. Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. *Diabetes Care*. 2013;36(12):3863-3869.
25. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. *Diabetes Care*. 2018;41(suppl 1):S13-S27.
26. Copeland KC, Zeitler P, Geffner M, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. *J Clin Endocrinol Metab*. 2011;96(1):159-167.
27. Libman IM, Barinas-Mitchell E, Bartucci A, Robertson R, Arslanian S. Reproducibility of the oral glucose tolerance test in overweight children. *J Clin Endocrinol Metab*. 2008;93(11):4231-4237.
28. Kapadia C, Zeitler P, Drugs and Therapeutics Committee of the Pediatric Endocrine Society. Hemoglobin A1c measurement for the diagnosis of type 2 diabetes in children. *Int J Pediatr Endocrinol*. 2012;2012(1):31.
29. Chan CL, Pyle L, Newnes L, Nadeau KJ, Zeitler PS, Kelsey MM. Continuous glucose monitoring and its relationship to hemoglobin A1c and oral glucose tolerance testing in obese and prediabetic youth. *J Clin Endocrinol Metab*. 2015;100(3):902-910.
30. Love-Osborne KA, Sheeder J, Svircev A, Chan C, Zeitler P, Nadeau KJ. Use of glycosylated hemoglobin increases diabetes screening for at-risk adolescents in primary care settings. *Pediatr Diabetes*. 2013;14(7):512-518.
31. Bergenstal RM, Gal RL, Connor CG, et al. Racial differences in the relationship of glucose concentrations and hemoglobin A1c levels. *Ann Intern Med*. 2017;167(2):95-102.
32. Diabetes Research in Children Network Study Group, Wilson DM, Kollman. Relationship of A1C to glucose concentrations in children with type 1 diabetes: assessments by high-frequency glucose determinations by sensors. *Diabetes Care*. 2008;31(3):381-385.
33. Bottazzo GF, Bosi E, Cull CA, et al. IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). *Diabetologia*. 2005;48(4):703-708.
34. Turner R, Stratton I, Horton V, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. *Lancet*. 1997;350(9087):1288-1293.
35. Umpaichitra V, Banerji MA, Castells S. Autoantibodies in children with type 2 diabetes mellitus. *J Pediatr Endocrinol Metab*. 2002;15(suppl 1):525-530.
36. Reinehr T, Schober E, Wiegand S, Thon A, Holl R, DP-Wiss Study Group. Beta-cell autoantibodies in children with type 2 diabetes mellitus: subgroup or misclassification? *Arch Dis Child*. 2006;91(6):473-477.
37. Klingensmith GJ, Pyle L, Arslanian S, et al. The presence of GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype: results from the TODAY study. *Diabetes Care*. 2010;33(9):1970-1975.
38. Laffel L, Chang N, Grey M, et al. Metformin monotherapy in youth with recent onset type 2 diabetes: experience from the prerandomization run-in phase of the TODAY study. *Pediatr Diabetes*. 2012;13(5):369-375.
39. Kelsey MM, Geffner ME, Guandalini C, et al. Presentation and effectiveness of early treatment of type 2 diabetes in youth: lessons from the TODAY study. *Pediatr Diabetes*. 2016;17(3):212-221.
40. Writing Group for the SfdiYSG, Dabelea D, Bell RA, et al. Incidence of diabetes in youth in the United States. *JAMA*. 2007;297(24):2716-2724.
41. Pinhas-Hamiel O, Standiford D, Hamiel D, Dolan LM, Cohen R, Zeitler PS. The type 2 family: a setting for development and treatment of adolescent type 2 diabetes mellitus. *Arch Pediatr Adolesc Med*. 1999;153(10):1063-1067.
42. Chan JC, Cheung CK, Swaminathan R, Nicholls MG, Cockram CS. Obesity, albuminuria and hypertension among Hong Kong Chinese with non-insulin-dependent diabetes mellitus (NIDDM). *Postgrad Med J*. 1993;69(809):204-210.
43. Haynes A, Kalic R, Cooper M, Hewitt JK, Davis EA. Increasing incidence of type 2 diabetes in Indigenous and non-Indigenous children in Western Australia, 1990-2012. *Med J Aust*. 2016;204(8):303.
44. Schober E, Holl RW, Grabert M, et al. Diabetes mellitus type 2 in childhood and adolescence in Germany and parts of Austria. *Eur J Pediatr*. 2005;164(11):705-707.
45. Schober E, Rami B, Grabert M, et al. Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database. *Diabet Med*. 2009;26(5):466-473.

46. Urakami T, Kuwabara R, Habu M, et al. Clinical characteristics of non-obese children with type 2 diabetes mellitus without involvement of beta-cell autoimmunity. *Diabetes Res Clin Pract.* 2013;99(2):105-111.
47. Rosenbloom AL. Obesity, insulin resistance, beta-cell autoimmunity, and the changing clinical epidemiology of childhood diabetes. *Diabetes Care.* 2003;26(10):2954-2956.
48. Dabelea D, Rewers A, Stafford JM, et al. Trends in the prevalence of ketoacidosis at diabetes diagnosis: the SEARCH for diabetes in youth study. *Pediatrics.* 2014;133(4):e938-e945.
49. Zeitler P, Haqq A, Rosenbloom A, Glaser N, Drugs and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Hyperglycemic hyperosmolar syndrome in children: pathophysiological considerations and suggested guidelines for treatment. *J Pediatr.* 2011;158(1):9-14.e2.
50. Tfayli H, Bacha F, Gungor N, Arslanian S. Phenotypic type 2 diabetes in obese youth: insulin sensitivity and secretion in islet cell antibody-negative versus -positive patients. *Diabetes.* 2009;58(3):738-744.
51. Tfayli H, Bacha F, Gungor N, Arslanian S. Islet cell antibody-positive versus -negative phenotypic type 2 diabetes in youth: does the oral glucose tolerance test distinguish between the two? *Diabetes Care.* 2010;33(3):632-638.
52. Rivera-Vega MY, Flint A, Winger DG, Libman I, Arslanian S. Obesity and youth diabetes: distinguishing characteristics between islet cell antibody positive vs. negative patients over time. *Pediatr Diabetes.* 2015;16(5):375-381.
53. Writing Team for the Diabetes C, Complications Trial/Epidemiology of Diabetes I, Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the epidemiology of diabetes interventions and complications (EDIC) study. *JAMA.* 2003;290(16):2159-2167.
54. Nadeau KJ, Regensteiner JG, Bauer TA, et al. Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function. *J Clin Endocrinol Metab.* 2010;95(2):513-521.
55. Nadeau KJ, Zeitler PS, Bauer TA, et al. Insulin resistance in adolescents with type 2 diabetes is associated with impaired exercise capacity. *J Clin Endocrinol Metab.* 2009;94(10):3687-3695.
56. Rubio-Cabezas O, Hattersley AT, Njolstad PR, et al. ISPAD clinical practice consensus guidelines 2014. The diagnosis and management of monogenic diabetes in children and adolescents. *Pediatr Diabetes.* 2014;15(suppl 20):47-64.
57. Dabelea D, Pihoker C, Talton JW, et al. Etiological approach to characterization of diabetes type: the SEARCH for Diabetes in Youth Study. *Diabetes Care.* 2011;34(7):1628-1633.
58. Cali' AMG, Bonadonna RC, Trombetta M, Weiss R, Caprio S. Metabolic abnormalities underlying the different prediabetic phenotypes in obese adolescents. *J Clin Endocrinol Metab.* 2008;93(5):1767-1773.
59. Bacha F, Lee S, Gungor N, Arslanian SA. From pre-diabetes to type 2 diabetes in obese youth: pathophysiological characteristics along the spectrum of glucose dysregulation. *Diabetes Care.* 2010;33(10):2225-2231.
60. Burns SF, Bacha F, Lee SJ, Tfayli H, Gungor N, Arslanian SA. Declining beta-cell function relative to insulin sensitivity with escalating OGTT 2-h glucose concentrations in the nondiabetic through the diabetic range in overweight youth. *Diabetes Care.* 2011;34(9):2033-2040.
61. Tfayli H, Lee S, Arslanian S. Declining beta-cell function relative to insulin sensitivity with increasing fasting glucose levels in the nondiabetic range in children. *Diabetes Care.* 2010;33(9):2024-2030.
62. Reinehr T, Wolters B, Knop C, Lass N, Holl RW. Strong effect of pubertal status on metabolic health in obese children: a longitudinal study. *J Clin Endocrinol Metab.* 2015;100(1):301-308.
63. Weiss R, Taksali SE, Tamborlane WV, Burgert TS, Savoye M, Caprio S. Predictors of changes in glucose tolerance status in obese youth. *Diabetes Care.* 2005;28(4):902-909.
64. Kleber M, deSousa G, Papcke S, Wabitsch M, Reinehr T. Impaired glucose tolerance in obese white children and adolescents: three to five year follow-up in untreated patients. *Exp Clin Endocrinol Diabetes.* 2011;119(3):172-176.
65. Kleber M, Lass N, Papcke S, Wabitsch M, Reinehr T, et al. One-year follow-up of untreated obese white children and adolescents with impaired glucose tolerance: high conversion rate to normal glucose tolerance. *Diabet Med.* 2010;27(5):516-521.
66. Love-Osborne KA, Sheeder JL, Nadeau KJ, Zeitler P. Longitudinal follow up of dysglycemia in overweight and obese pediatric patients. *Pediatr Diabetes.* 2018;19(2):199-204.
67. Khokhar A, Umpaichitra V, Chin VL, Perez-Colon S. Metformin use in children and adolescents with prediabetes. *Pediatr Clin North Am.* 2017;64(6):1341-1353.
68. Lindsay RS, Hanson RL, Bennett PH, Knowler WC. Secular trends in birth weight, BMI, and diabetes in the offspring of diabetic mothers. *Diabetes Care.* 2000;23(9):1249-1254.
69. Dabelea D, Mayer-Davis EJ, Lamichhane AP, et al. Association of intrauterine exposure to maternal diabetes and obesity with type 2 diabetes in youth: the SEARCH Case-Control Study. *Diabetes Care.* 2008;31(7):1422-1426.
70. Dart AB, Martens PJ, Rigatto C, Brownell MD, Dean HJ, Sellers EA. Earlier onset of complications in youth with type 2 diabetes. *Diabetes Care.* 2014;37(2):436-443.
71. TODAY Study Group. Retinopathy in youth with type 2 diabetes participating in the TODAY clinical trial. *Diabetes Care.* 2013;36(6):1772-1774.
72. TODAY Study Group. Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. *Diabetes Care.* 2013;36(6):1758-1764.
73. Marcus MD, Wilfley DE, El Ghormli L, et al. Weight change in the management of youth-onset type 2 diabetes: the TODAY clinical trial experience. *Pediatr Obes.* 2017;12(4):337-345.
74. Berkowitz RI, Marcus MD, Anderson BJ, et al. Adherence to a lifestyle program for youth with type 2 diabetes and its association with treatment outcome in the TODAY clinical trial. *Pediatr Diabetes.* 2018;19(2):191-198.
75. Reinehr T, Schober E, Roth CL, Wiegand S, Holl R. Type 2 diabetes in children and adolescents in a 2-year follow-up: insufficient adherence to diabetes centers. *Horm Res.* 2008;69(2):107-113.
76. Smart CE, Annan F, Bruno LP, et al. ISPAD Clinical Practice Consensus Guidelines 2014. Nutritional management in children and adolescents with diabetes. *Pediatr Diabetes.* 2014;15(suppl 20):135-153.
77. Cameron FJ, Amin R, de Beaufort C, et al. ISPAD Clinical Practice Consensus Guidelines 2014. Diabetes in adolescence. *Pediatr Diabetes.* 2014;15(suppl 20):245-256.
78. Copeland KC, Silverstein J, Moore KR, et al. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. *Pediatrics.* 2013;131(2):364-382.
79. Barlow SE, Expert C. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. *Pediatrics.* 2007;120(suppl 4):S164-S192.
80. Fitch C, Keim KS, Academy of Nutrition and Dietetics. Position of the Academy of Nutrition and Dietetics: use of nutritive and nonnutritive sweeteners. *J Acad Nutr Diet.* 2012;112(5):739-758.
81. American Diabetes Association. 4. Lifestyle management: standards of medical care in diabetes-2018. *Diabetes Care.* 2018;41(suppl 1):S38-S50.
82. Dhuper S, Buddha S, Patel S. Managing cardiovascular risk in overweight children and adolescents. *Paediatr Drugs.* 2013;15(3):181-190.
83. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. *Circulation.* 2014;129(25 suppl 2):S102-S138.
84. Chahal H, Fung C, Kuhle S, Veugelers PJ. Availability and night-time use of electronic entertainment and communication devices are associated with short sleep duration and obesity among Canadian children. *Pediatr Obes.* 2013;8(1):42-51.



85. Lane A, Harrison M, Murphy N. Screen time increases risk of overweight and obesity in active and inactive 9-year-old Irish children: a cross sectional analysis. *J Phys Act Health*. 2014;11(5):985-991.
86. Ash T, Taveras EM. Associations of short sleep duration with childhood obesity and weight gain: summary of a presentation to the National Academy of Science's Roundtable on Obesity Solutions. *Sleep Health*. 2017;3(5):389-392.
87. Robinson TN. Reducing children's television viewing to prevent obesity: a randomized controlled trial. *JAMA*. 1999;282(16):1561-1567.
88. Mays D, Streisand R, Walker LR, Prokhorov AV, Tercyak KP. Cigarette smoking among adolescents with type 1 diabetes: strategies for behavioral prevention and intervention. *J Diabetes Complications*. 2012;26(2):148-153.
89. American Diabetes Association. 12. Children and adolescents: standards of medical care in diabetes-2018. *Diabetes Care*. 2018;41(suppl 1):S126-S136.
90. Zeitler P, Hirst K, Copeland KC, et al. HbA1c after a short period of monotherapy with metformin identifies durable glycemic control among adolescents with type 2 diabetes. *Diabetes Care*. 2015;38(12):2285-2292.
91. American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. *Diabetes Care*. 2018;41(suppl 1):S73-S85.
92. Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2013;98(12):4565-4592.
93. TODAY Study Group. Safety and tolerability of the treatment of youth-onset type 2 diabetes: the TODAY experience. *Diabetes Care*. 2013;36(6):1765-1771.
94. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. *JAMA*. 2007;298(10):1180-1188.
95. Gottschalk M, Danne T, Vlainic A, Cara JF. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. *Diabetes Care*. 2007;30(4):790-794.
96. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. *N Engl J Med*. 2006;355(23):2427-2443.
97. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. *JAMA*. 2007;298(10):1189-1195.
98. Tuccori M, Filion KB, Yin H, Yu OH, Platt RW, Azoulay L. Pioglitazone use and risk of bladder cancer: population based cohort study. *BMJ*. 2016;352:i1541.
99. Yang W, Liu J, Shan Z, et al. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial. *Lancet Diabetes Endocrinol*. 2014;2(1):46-55.
100. Mann JFE, Orsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. *N Engl J Med*. 2017;377(9):839-848.
101. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2016;375(4):311-322.
102. Klein DJ, Battelino T, Chatterjee DJ, et al. Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial. *Diabetes Technol Ther*. 2014;16(10):679-687.
103. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*. 2015;373(22):2117-2128.
104. Cherney DZI, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. *Lancet Diabetes Endocrinol*. 2017;5(8):610-621.
105. Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). *Circulation*. 2018;137(4):323-334.
106. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med*. 2017;377(7):644-657.
107. Nicolle LE, Capuano G, Fung A, Usiskin K. Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. *Postgrad Med*. 2014;126(1):7-17.
108. Tanaka A, Node K. Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit? *Cardiovasc Diabetol*. 2017;16(1):129.
109. Shoukat S, Usmani NA, Soetan O, Qureshi F. Euglycemic diabetic ketoacidosis accompanied by severe hypophosphatemia during recovery in a patient with type 2 diabetes being treated with Canagliflozin/metformin combination therapy. *Clin Diabetes*. 2017;35(4):249-251.
110. Inge TH, Jenkins TM, Xanthakos SA, et al. Long-term outcomes of bariatric surgery in adolescents with severe obesity (FABS-5+): a prospective follow-up analysis. *Lancet Diabetes Endocrinol*. 2017;5(3):165-173.
111. Stefater MA, Inge TH. Bariatric surgery for adolescents with type 2 diabetes: an emerging therapeutic strategy. *Curr Diab Rep*. 2017;17(8):62.
112. Ibanez L, Potau N, Marcos MV, de Zegher F. Exaggerated adrenarche and hyperinsulinism in adolescent girls born small for gestational age. *J Clin Endocrinol Metab*. 1999;84(12):4739-4741.
113. Dabelea D, Crume T. Maternal environment and the transgenerational cycle of obesity and diabetes. *Diabetes*. 2011;60(7):1849-1855.
114. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). *JAMA*. 2001;285(19):2486-2497.
115. Ford ES, Li C. Defining the metabolic syndrome in children and adolescents: will the real definition please stand up? *J Pediatr*. 2008;152(2):160-4.e13.
116. Reinehr T. Metabolic syndrome in children and adolescents: a critical approach considering the interaction between pubertal stage and insulin resistance. *Curr Diab Rep*. 2016;16(1):8.
117. Reinehr T, Wunsch R, Putter C, Scherag A. Relationship between carotid intima-media thickness and metabolic syndrome in adolescents. *J Pediatr*. 2013;163(2):327-32.e4.
118. Zimmet P, Alberti KG, Kaufman F, et al. The metabolic syndrome in children and adolescents – an IDF consensus report. *Pediatr Diabetes*. 2007;8(5):299-306.
119. Laurson KR, Welk GJ, Eisenmann JC. Diagnostic performance of BMI percentiles to identify adolescents with metabolic syndrome. *Pediatrics*. 2014;133(2):e330-e338.
120. Chinese Work Group of Pediatric Metabolic Syndrome. Prevalence of metabolic syndrome of children and adolescent students in Chinese six cities. *Zhonghua Er Ke Za Zhi*. 2013;51(6):409-413.
121. Tandon N, Garg MK, Singh Y, Marwaha RK. Prevalence of metabolic syndrome among urban Indian adolescents and its relation with insulin resistance (HOMA-IR). *J Pediatr Endocrinol Metab*. 2013;26(11-12):1123-1130.
122. Amutha A, Anjana RM, Venkatesan U, et al. Incidence of complications in young-onset diabetes: comparing type 2 with type 1 (the young diab study). *Diabetes Res Clin Pract*. 2017;123:1-8.
123. Donaghue KC, Wadwa RP, Dimeglio LA, et al. ISPAD Clinical Practice Consensus Guidelines 2014. Microvascular and macrovascular complications in children and adolescents. *Pediatr Diabetes*. 2014;15(suppl 20):257-269.
124. Kordonouri O, Klingensmith G, Knip M, et al. ISPAD Clinical Practice Consensus Guidelines 2014. Other complications and diabetes-associated conditions in children and adolescents. *Pediatr Diabetes*. 2014;15(suppl 20):270-278.
125. Freedman DS, Khan LK, Dietz WH, Srinivasan SR, Berenson GS. Relationship of childhood obesity to coronary heart disease risk factors in adulthood: the Bogalusa Heart Study. *Pediatrics*. 2001;108(3):712-718.

126. Berenson GS, Srinivasan SR, Bogalusa Heart Study Group. Cardiovascular risk factors in youth with implications for aging: the Bogalusa Heart Study. *Neurobiol Aging*. 2005;26(3):303-307.
127. Juonala M, Jarvisalo MJ, Maki-Torkko N, Kahonen M, Viikari JS, Raitakari OT. Risk factors identified in childhood and decreased carotid artery elasticity in adulthood: the Cardiovascular Risk in Young Finns Study. *Circulation*. 2005;112(10):1486-1493.
128. Marcus MD, Foster GD, El Ghormli L, et al. Shifts in BMI category and associated cardiometabolic risk: prospective results from HEALTHY study. *Pediatrics*. 2012;129(4):e983-e991.
129. Styne DM, Arslanian SA, Connor EL, et al. Pediatric obesity-assessment, treatment, and prevention: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2017;102(3):709-757.
130. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lungs, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. *Pediatrics*. 2011;128(suppl 5):S213-S256.
131. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ*. 1998;317(7160):703-713.
132. Eppens MC, Craig ME, Cusumano J, et al. Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. *Diabetes Care*. 2006;29(6):1300-1306.
133. West NA, Hamman RF, Mayer-Davis EJ, et al. Cardiovascular risk factors among youth with and without type 2 diabetes: differences and possible mechanisms. *Diabetes Care*. 2009;32(1):175-180.
134. Batsisky DL. What is the optimal first-line agent in children requiring antihypertensive medication? *Curr Hypertens Rep*. 2012;14(6):603-607.
135. Blowey DL. Update on the pharmacologic treatment of hypertension in pediatrics. *J Clin Hypertens (Greenwich)*. 2012;14(6):383-387.
136. American Diabetes Association. 9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018. *Diabetes Care*. 2018;41(suppl 1):S86-S104.
137. Ettinger LM, Freeman K, DiMartino-Nardi JR, Flynn JT. Microalbuminuria and abnormal ambulatory blood pressure in adolescents with type 2 diabetes mellitus. *J Pediatr*. 2005;147(1):67-73.
138. McGrath NM, Parker GN, Dawson P. Early presentation of type 2 diabetes mellitus in young New Zealand Maori. *Diabetes Res Clin Pract*. 1999;43(3):205-209.
139. Sellers EAC, Yung G, Dean HJ. Dyslipidemia and other cardiovascular risk factors in a Canadian First Nation pediatric population with type 2 diabetes mellitus. *Pediatr Diabetes*. 2007;8(6):384-390.
140. Dart AB, Sellers EA, Martens PJ, Rigatto C, Brownell MD, Dean HJ. High burden of kidney disease in youth-onset type 2 diabetes. *Diabetes Care*. 2012;35(6):1265-1271.
141. Yokoyama H, Okudaira M, Otani T, et al. Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. *Kidney Int*. 2000;58(1):302-311.
142. Rodriguez BL, Fujimoto WY, Mayer-Davis EJ, et al. Prevalence of cardiovascular disease risk factors in U.S. children and adolescents with diabetes: the SEARCH for diabetes in youth study. *Diabetes Care*. 2006;29(8):1891-1896.
143. Huang K, Zou CC, Yang XZ, Chen XQ, Liang L. Carotid intima-media thickness and serum endothelial marker levels in obese children with metabolic syndrome. *Arch Pediatr Adolesc Med*. 2010;164(9):846-851.
144. Nadeau KJ, Maahs DM, Daniels SR, Eckel RH. Childhood obesity and cardiovascular disease: links and prevention strategies. *Nat Rev Cardiol*. 2011;8(9):513-525.
145. Levitt Katz L, Gidding SS, Bacha F, et al. Alterations in left ventricular, left atrial, and right ventricular structure and function to cardiovascular risk factors in adolescents with type 2 diabetes participating in the TODAY clinical trial. *Pediatr Diabetes*. 2015;16(1):39-47.
146. Flint A, Arslanian S. Treatment of type 2 diabetes in youth. *Diabetes Care*. 2011;34(suppl 2):S177-S183.
147. Wadwa RP, Urbina EM, Anderson AM, et al. Measures of arterial stiffness in youth with type 1 and type 2 diabetes: the SEARCH for diabetes in youth study. *Diabetes Care*. 2010;33(4):881-886.
148. Lewy VD, Danadian K, Witchel SF, Arslanian S. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. *J Pediatr*. 2001;138(1):38-44.
149. Amini M, Horri N, Farmani M, et al. Prevalence of polycystic ovary syndrome in reproductive-aged women with type 2 diabetes. *Gynecol Endocrinol*. 2008;24(8):423-427.
150. Shafiee MN, Khan G, Ariffin R, et al. Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help? *Gynecol Oncol*. 2014;132(1):248-253.
151. Nadeau KJ, Klingensmith G, Zeitler P. Type 2 diabetes in children is frequently associated with elevated alanine aminotransferase. *J Pediatr Gastroenterol Nutr*. 2005;41(1):94-98.
152. Newton KP, Hou J, Crimmins NA, et al. Prevalence of prediabetes and type 2 diabetes in children with nonalcoholic fatty liver disease. *JAMA Pediatr*. 2016;170(10):e161971.
153. Roberts EA. Non-alcoholic fatty liver disease (NAFLD) in children. *Front Biosci*. 2005;10:2306-2318.
154. Hudson OD, Nunez M, Shaibi GQ. Ethnicity and elevated liver transaminases among newly diagnosed children with type 2 diabetes. *BMC Pediatr*. 2012;12:174.
155. Sundaram SS, Zeitler P, Nadeau K. The metabolic syndrome and non-alcoholic fatty liver disease in children. *Curr Opin Pediatr*. 2009;21(4):529-535.
156. Zhang HX, Fu JF, Huang K, Lai C, Liang L, Jiang KW. Quantitative assessment of intrahepatic fat content in children and adolescents with non-alcoholic fatty liver disease. *Zhongguo Dang Dai Er Ke Za Zhi*. 2012;14(8):598-603.
157. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. *Hepatology*. 1999;30(6):1356-1362.
158. Reinehr T, Schmidt C, Toschke AM, Andler W. Lifestyle intervention in obese children with non-alcoholic fatty liver disease: 2-year follow-up study. *Arch Dis Child*. 2009;94(6):437-442.
159. Rice TB, Foster GD, Sanders MH, et al. The relationship between obstructive sleep apnea and self-reported stroke or coronary heart disease in overweight and obese adults with type 2 diabetes mellitus. *Sleep*. 2012;35(9):1293-1298.
160. Foster GD, Sanders MH, Millman R, et al. Obstructive sleep apnea among obese patients with type 2 diabetes. *Diabetes Care*. 2009;32(6):1017-1019.
161. Shaw JE, Punjabi NM, Wilding JP, Alberti KG, Zimmet PZ, International Diabetes Federation Taskforce on Epidemiology and Prevention. Sleep-disordered breathing and type 2 diabetes: a report from the International Diabetes Federation Taskforce on Epidemiology and Prevention. *Diabetes Res Clin Pract*. 2008;81(1):2-12.
162. Walders-Abramson N. Depression and quality of life in youth-onset type 2 diabetes mellitus. *Curr Diab Rep*. 2014;14(1):449.
163. Pervanidou P, Chrousos GP. Metabolic consequences of stress during childhood and adolescence. *Metabolism*. 2012;61(5):611-619.
164. Anderson BJ, Edelstein S, Abramson NW, et al. Depressive symptoms and quality of life in adolescents with type 2 diabetes: baseline data from the TODAY study. *Diabetes Care*. 2011;34(10):2205-2207.
165. Lawrence JM, Standiford DA, Loots B, et al. Prevalence and correlates of depressed mood among youth with diabetes: the SEARCH for diabetes in youth study. *Pediatrics*. 2006;117(4):1348-1358.
166. Walders-Abramson N, Venditti EM, Ievers-Landis CE, et al. Relationships among stressful life events and physiological markers, treatment adherence, and psychosocial functioning among youth with type 2 diabetes. *J Pediatr*. 2014;165(3):504-8 e1.
167. Browne JL, Nefs G, Pouwer F, Speight J. Depression, anxiety and self-care behaviours of young adults with type 2 diabetes: results from the International Diabetes Management and Impact for Long-term Empowerment and Success (MILES) Study. *Diabet Med*. 2015;32(1):133-140.
168. Pinhas-Hamiel O, Levy-Shraga Y. Eating disorders in adolescents with type 2 and type 1 diabetes. *Curr Diab Rep*. 2013;13(2):289-297.
169. TODAY Study Group, Wilfley D, Berkowitz R, et al. Binge eating, mood, and quality of life in youth with type 2 diabetes: baseline data from the today study. *Diabetes Care*. 2011;34(4):858-860.

170. Weinstock RS, Trief PM, El Ghormli L, et al. Parental characteristics associated with outcomes in youth with type 2 diabetes: results from the TODAY clinical trial. *Diabetes Care*. 2015;38(5):784-792.
171. Rhodes ET, Prosser LA, Hoerger TJ, Lieu T, Ludwig DS, Laffel LM. Estimated morbidity and mortality in adolescents and young adults diagnosed with type 2 diabetes mellitus. *Diabet Med*. 2012;29(4):453-463.
172. Hillier TA, Pedula KL. Complications in young adults with early-onset type 2 diabetes: losing the relative protection of youth. *Diabetes Care*. 2003;26(11):2999-3005.
173. Wong J, Molyneaux L, Constantino M, Twigg SM, Yue DK. Timing is everything: age of onset influences long-term retinopathy risk in type 2 diabetes, independent of traditional risk factors. *Diabetes Care*. 2008;31(10):1985-1990.
174. Al-Saeed AH, Constantino MI, Molyneaux L, et al. An inverse relationship between age of type 2 diabetes onset and complication risk and mortality: the impact of youth-onset type 2 diabetes. *Diabetes Care*. 2016;39(5):823-829.
175. Sackett DL, Holland WW. Controversy in the detection of disease. *Lancet*. 1975;2(7930):357-359.
176. Baranowski T, Cooper DM, Harrell J, et al. Presence of diabetes risk factors in a large U.S. eighth-grade cohort. *Diabetes Care*. 2006;29(2):212-217.
177. Type 2 diabetes in children and adolescents. American Diabetes Association. *Diabetes Care*. 2000;23(3):381-389.
178. Urakami T, Kubota S, Nitadori Y, Harada K, Owada M, Kitagawa T. Annual incidence and clinical characteristics of type 2 diabetes in children as detected by urine glucose screening in the Tokyo metropolitan area. *Diabetes Care*. 2005;28(8):1876-1881.
179. Wei JN, Chuang LM, Lin CC, Chiang CC, Lin RS, Sung FC. Childhood diabetes identified in mass urine screening program in Taiwan, 1993-1999. *Diabetes Res Clin Pract*. 2003;59(3):201-206.

**How to cite this article:** Zeitler P, Arslanian S, Fu J, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Type 2 diabetes mellitus in youth. *Pediatr Diabetes*. 2018;19(Suppl. 27):28-46. <https://doi.org/10.1111/pedi.12719>